Transcript
0:07 India makes medicines that heals billions of people across the [music] world. Most of them have no idea who's behind it. [music] After much demand, we [music] brought together two of India's farmer giants, Dr. the Reddis and Mankind [music] to help you, the young entrepreneurs of this country, grasp [music] the industry's nuances. Their products are household names, probably consumed by you at some time [music] and of course consumed by millions. So, we decided to put a face to these tall [music] birds.
0:45 So, how do you talk yourself into it every day? >> Supposed to prove it to my family, to my brother that I'm worth something. So that talk was only one that uh how can I make it to a level that I can start respecting myself >> and I'm sure you've been through multiple phases [music] of going through tough times. >> Um the biggest challenge I ever had was in our operations. [snorts] This happened in the mid uh last decade in the middle of the last decade around we had safety incidents where you know people died and that really shook me up and really put me in a deep state of depression. So that was a very difficult time for me.
1:33 >> Deli pharmaceuticals is headed by Ji [music] Prasad and brings in roughly 3 billion in revenue. Mankind is led by Rajiv Junja and his [music] brother with an annual turnover of about 40,000 crores. [music] With numbers like these, many would coast but not Rajie or Gi. Their hunger keeps pushing the boundaries. [music] Here's the thing nobody tells you. India is called the pharmacy of the world, but that's by [music] volume. By revenue, we're barely a rounding error.
2:09 We make the drugs, but someone else makes the money. So, who and why? And more importantly, [music] where does a 25-year-old find an opening in all of this? That's exactly what we asked. What is the business opportunity here? Can you guys think of anything else for the 25year-old? There are one in 28 unicorns in India today. There is one in pharma drug innovation. >> [music] [music] [music] [music] [music] [music] [music] >> But this is very casual. I was telling him earlier, Prasad, >> he our audience is largely young people who want to start a business in your industry.
3:49 >> So we won't speak so much about your company in particular. There's nothing controversial. There's no kind of stuff. It's very much everything a 25 year old needs to start a business in the pharma industry. So think both of you are professors today and you are teaching a class of young 25 year olds. I'm part of that class. So I will keep asking the question before we start maybe you guys can tell me a bit about yourselves. I know you guys already successful popular people but a little bit about your life and how you got to be where you are. You like to go first?
4:27 >> I can go first. I don't have any issues. My my name is Rajiv Junja and my I have one wife [laughter] and I have five kids, three daughters, two sons. I mean daughters means I mean they are daughter-in-laws and one grand daughter. So I come from um a place called Mirat which is 60 kilometers away from u Delhi. I'm a I'm new in Delhi. um 20045 we came to Delhi and before that uh uh my education my brought up all was in merit and uh I'm a college dropout because uh circumstances were like this and uh number one I was not interested in study studies and so that's why I got an excuse that uh there's a compulsion in the family and the money is not there so uh I used to go to uh my brother's medical store that I learned how to run a pharmacy like people go to Nani's place in summer vacation I used to go to that medical store for 2 months so 8 9 months I worked over there that was from 10th class to PC part one then one day I said I want to be a medical rep I became a medical rep in my brother's company worked 10 years over there and uh there I did a lot of and started a company called Mankind in 1995.
5:57 >> 1995. >> 95. Yeah, >> it's been that long. >> Yeah. 30 years. >> Wow. >> It's been a while. >> Just one second. Don't uh leave him open. >> I'm telling him don't keep the chain. Okay, let's continue. >> Today, whatever mankind is is because of uh whatever I'll say destiny dictates. >> How did it go from pharmaceutical to what like my experience of working in a pharmaceutical store and starting what was >> uh see what basically happens in life what you hate um becomes a big lesson for you. I used to hate going to the pharmacy, cleaning, sweeping, buying goods from wholesale market. I mean uh at the age when my friends were enjoying uh so that was the lesson how market really work, how sales reps, how companies, how doctors um operate, how this market operates. I never knew that. And then I became a medical rep uh in every local kind of a company. It was local means in the sense that like black and white company not even colors were there in boxes and visual aids or literatures. So when you work in that kind of a company uh if you will not become a brand yourself uh company will not run. Uh where failure rate is 80 90%.
7:39 every time just you you become so thick skinned at the same time sensitive. I mean it was uh somewhat oxymoron. Same time you are zi or thick skinned same time you're very very sensitive. uh when you go through that kind of a phase and these two enable that uh one time that company start which was started with 69,000 rupees in 84 became merit's number one company we had written black so any company everybody every company sheer hard work sheer hard work that's it I mean many of this kind of something could really happens. We were almost Western UP's top 10 companies and then um some family separation was there. Sumi and my brother said uh we'll start a new company and we got 50 lakh rupees and in those days bestoare was 10 cr revenue company that's just a very peaceful partition and we wanted to get away every learning was not in mankind every learning happened during that time of huge struggle.
9:00 >> What is mankind today? Can you explain that? uh mankind today is fourth largest farmer company uh the revenue of more than 40,000 cr rupees. We are the company which uh operates in veterary side as well. We operate in pet side as well. We are a OTC company as well. Uh >> what's the biggest part of >> the biggest biggest part is pharma.
9:30 Biggest parts uh say 85% is pharma. >> One particular product you get. >> Yeah. Uh one product which is uh quite a big one is tell me kind it's for hypertension 1,000 k rupees. Yeah. Second brand would be manosforce. That's quite a known name. Condoms around uh together 600 cr rupees. That is what mankind mankind is basically people say it's a OTC kind of a company uh because of man force but u if you just look and go deeper down it's a farmer company.
10:11 Intentionally we started um OTC because we wanted to be known. when you start very small. We started from merit and we are nothing. Um and uh we never ever started all India and Mango. First western UP only first made a try and slowly and gradually eastern UP then Hana then Punjab basically evolved wherever we went. It's like we were a small company rising very fast.
10:45 So after all this what you basically see is respect name and how can you get the name then you come on television. How can you come on television as a farmer company you cannot come. So launch see man your OTC company would be there in the end your logo would be displayed and we used to keep logo for a longer period otherwise just generally it's uh half a second we used to keep it for more than a second that was the strategy magazines newspaper every place so actually uh we basically wanted to propagate mankind all over India before mankind is to be launched any place southside we were not there we came came to south 19 years back we are 30 years old but it was all gradual we were not in a hurry our India was UP our India became Hariana and Punjab and then UP our India we never thought that India is one or focused it was always very focused approach deepest coverage and uh he's a scientist he's a different guy u he he come from that uh top side of the pyramid of uh pharma R&D and uh other things I >> used to think of you guys like commandos come in and push forward all the competition I said go ahead >> I mean we we basically call ourselves I mean FMCP FMCG of fararma >> I mean uh we had nothing uh same branded generate 20 brands.
12:29 >> But you are very unconventional. >> Yeah. >> All you brought into the market. >> How you pushed out? >> Never followed anything of the industry. N were absolutely contrarian 100%. And even even right now if everybody's doing something I will not do. If something is fry. >> What are you most bullish about? Is it uh G part of G part of SMC or B to F?
13:00 >> I'm most bullish now. I mean as you basically evolve um we are going to come in this category. >> In which category? >> In his category. These guys get very young R&D guys. That's our next goal. And >> you guys like >> never go in and sit mosquito time and >> 15 minutes there'll be mosquitoes. >> It's Sunday here. >> But I mean if you if you just ask me mosquitoes in Delhi versus this place no mosquitoes. I can't see.
13:34 >> No they come strange at one particular time at 5:45 >> they suddenly come and then at 6:30 you're not working. which is very speaking from where they come from. But from beginning [music] [music] up, change can change.
14:16 >> [music] >> So for starters, I wanted to understand [music] what did your first day in pharma look like? Uh nervous, bad, very bad. I ran away. I I will lie to my brother that that I worked because I had no confidence in meeting going in a medical college.
14:46 That was the first. >> What did your 1980s look like? >> Kind of wild. I was in college till it was 82 83. 82 83 I was doing my masters. Decided not to study. >> Yeah. experienced everything that life had to offer. So went to concerts, went to games. That's how my 83 was. I came back um joined my family business which was uh in construction but also I started an entrepreneurial venture in pharmaceuticals.
15:23 Ran that for some time. It didn't do too well. Then I exited. >> [music] >> And what is something in pharma that you have seen from 1980s to now that has changed so significantly in India? >> I think u you know when we started our business you just had to make the product to make money. [music] Now we have to be very good, excellent, highly competitive. The business has become very crowded. There are not many people here and it the whole thing has scaled.
16:00 >> [music] >> What was that day when you thought you have you have arrived? >> Maybe third year. >> Okay. >> Third year. >> And what do you think changed that day? >> I found few mentors actually to [music] be very honest. Uh I can call them mentors now. Uh in those days they were my gurus or whatever you call it. I made a choice that uh I should be in the company of smart people >> and [music] did something you know significantly shift when you say okay [music] I have made it now and I don't need to be worried what was that moment like did you buy something [music] did you have access to something that you didn't have before what was that >> till now that day has not come >> honestly >> have you always loved science >> I always like science yeah >> interesting I really loved it because you know it's like magic. You take simple molecules, combine them to make complex molecules and suddenly this molecule cures a disease.
17:07 >> And what made you come back? >> I was always [music] u I never thought I'd settle in the US >> really. I mean that's so different for so many people who grew up in that era. >> I think business families generally expect their children to come back. So I was kind of >> and what would your advice be for someone who's growing up in a business? >> At that time actually I wanted to do a PhD but I got admission but my father's business he was going through some trouble and asked me to come back and join it. I'd asked people now to do what they love to do what their dream is.
17:42 >> Fate has [music] its own way. Mr. Ji Prasad came back to India to run the family construction business. [music] He then went on to start his first pharmaceutical venture with his father. Their factory was right next to one belonging to Dr. Anji Reddi who was already a successful entrepreneur. Around this time he got married to Anurraha Reddi who was Dr. Reddy's daughter. [music] In 1988 the new pharma venture was not scaling and his father-in-law growing fast and needing capacity [music] for Dr. Readyy's laboratories bought the plant and merged it with his ji prasad moved on went back to construction and then one day the phone rang. Dr. Reddi was running two companies at the time chemol drugs and Dr. Reddy's laboratories. The co-founder of chemol drugs had parted ways due to differences. Dr. Reddi needed someone [music] he could trust.
18:42 Ji Prasad said yes without thinking. That was 1990. [music] He became the CEO of Keor Drugs. [music] The group was doing under 100 crores. He ran one company, built it, scaled it and in 2001, Chem merged with Dr. Ready's and was listed on NBS. Before Dr. Anji Reddi passed, he wrote a book. He called it the unfinished [music] agenda. A dream of discovering new molecules, new cures, a truly Indian pharmaceutical legacy. He didn't live to see it completed. The effort still continues through Origene Oncology.
19:27 [music] [music] Mix it at the table so we get light. >> Yes sir. >> So what would you say is the one differentiating advice that you would give to someone who's building in [music] the space >> in farmer?
19:59 >> Yeah. >> I'd say be careful which part of the business you're entering. Enter a space where there is room to play, grow and mistakes can be tolerated. [music] Focus on where your strength lies, where your competitive advantage will [music] be, what problem that you're solving in a unique way and get into that. Think through all this before you jump in.
20:34 These are a little more popular actually. Oh, and Jamie Roy. >> Sa is quite rare because normally he paints portraits. >> He doesn't paint full size. >> It's very interesting cuz you look at somebody who's like a handicapped man >> being carried. Then you look at the man carrying the handicapped person is also handicapped. It's kind of saying to society that people who look strong are also >> he's a quite popular one. [music] No, >> these are all popular. Souza, Jami, >> Roy is my city.
21:16 >> That is the last supper. >> But all the characters have been changed to [music] artists. >> Oh, really? >> Yeah. >> Yeah. Yeah. So, you see MF Hussein, you see >> Dali. Oh, really? >> Yeah. >> This is very interesting. >> Is in the center. >> Yeah. There's Rembrandt. There's Van Go. There's Andy Warhol. >> Some It's a paint or what? No, Chip. >> It's that graphite pen pencil. >> Who Who's the guy who just did this again?
21:48 >> Germany, right? Right. Maybe. [music] >> Very good. Who is this? >> These are Italian painter from 300 year ago. 300 years ago, 1700s. He's a master, [music] but his name is not attributed. >> It's like a unverified one. >> Yes. >> That one Kiran gave me actually. >> Which one? This one? >> Yeah. >> Oh, this one. >> The one about >> So Kiran's husband >> looks like a Irish one. >> Correct. So John >> Yeah, John's. Yeah.
22:18 >> This is from somewhere near John's uh house. If you just look at the paintings and if nobody tells you as an artist >> what is the meaning just >> a blank canvas is great. [music] >> I have a lot of stuff to ask you guys. >> Who did the search from your team? >> Uh Rashan.
22:49 >> He told me. Yeah. >> Yeah. Rashan get the research on this one. Okay. So you said you want to start with establishing the Indian pharma industry then we get into the different molecules and >> different modalities. >> Yeah. >> Right. >> Okay. So um let me start with segmenting the industry first >> and then we'll talk about the evolution of that segment and I think Raj >> we'll focus on Raji more for business and >> perfectly fine >> professor Prasad more on science >> even I'm learning from him I certain things I mean I keep talking to my R&D guy >> and he explains me things then it really goes away because my mind is always there somewhere else >> right actually I'm not a scientist also I'm a business guy >> see I mean But you have spent so many years >> Yeah.
23:38 >> over there in majorly science side you become knowledgeable. >> Yeah. [laughter] Yeah. >> For me you're a scientist. >> Yeah. So let me start with the segmentation. >> Okay. >> Broadly the industry has four or five verticals if you call them in IT language. >> API active ingredient. You want to start by biggest vertical to smallest >> in from an Indian context the biggest one is pharmaceuticals.
24:09 >> Okay. >> Generic pharmaceuticals. >> Generic farmer is the biggest. >> They're branded generics actually uh is the biggest vertical. It's actually copies of products which were discovered innovated by major pharmaceuticals around the world. We make them equivalent to them. And there's a whole study on how do you manage equivalence. I don't know if you want to know that. >> So you explain how a drug is discovered. Yeah. >> Then you explain patent. >> So once the patent runs out, then the generic starts or >> even before it runs out, you can do the R&D work, >> keep it ready for the day the patent expires and then sell it.
24:44 >> How does a American I'm just saying American, European, whatever company decide >> which pharmaceutical company in India, China, whichever country do they give the contract to? >> They don't get anything. They don't have a say of this. Anybody who wants to do it after the patent expires is free to do it. Uh so it's like this. The innovator discovers drugs. >> He has a protective monopoly for a few few years. >> Once Yeah. It depends on >> once the patent runs out.
25:14 >> You can anybody in the world can develop an equivalent product but they have to get it registered with the health authorities that it is really an equivalent product and then they can develop the product get it registered and sell it. How do you register the health authority will >> Yeah, I'll tell you how that is done. So you have a product discovered by FISA or you say semlutide discovered by no one else. It's an injection. Injections are simpler in some ways because you just have to establish analytically that they are the same solution that you are putting in the body. Sometimes they're not. Then you have to do studies on humans. M >> tablets you have to establish that the release of the drug in your body >> Mhm.
25:59 >> is equivalent to the way the innovators product is released in the body. Right? When you take a pill, >> you it goes into your digestive tract, >> it passes the thing and it goes into your bloodstream and then ultimately the liver uh kind of cleanses it out of your system. But in this interim, the the blood takes it to where it's supposed to go and the ingredient acts on the cells that it needs to act and cures your disease. It's like a lock and key. The protein is there and your drug goes there and uh corrects whatever needs to be corrected. M >> so there is a concentration of the product in your blood when you take a tablet for the next 24 hours 28 hours whatever it goes up the concentration goes up then it's cleansed out of your system >> so this is called the concentration curve >> you have to match that >> is that a big science when it is released >> not really I mean it's from coinetics for a person in the heart it's not so complicated >> you develop a formulation which is >> and that binding material the quality significantly different from a >> no no the binding doesn't happen because of anything extraneous >> the product itself itself is designed to bind >> right >> so the molecule it's like you have a lock it's a key which goes in and turns >> right does the then what like say for example there's one drug >> which should dissolve after I don't know like 30 seconds one more after 3 minutes >> so what changes that >> the way you formulate the product the the quality of the the characteristics of the substance >> and the way you formulate it, how you make a tablet, >> right?
27:37 >> How do you make it with what you make it? Active ingredient is one part of it. Then you have inactive ingredients, you have fillers, you have promoters, all those things which help the product dissolve in your body and act in your body in the right way. >> Right? So let me just simplify this in the sense of what is a generic for you. >> So you have a tablet you take >> and it works for you.
27:59 >> This is innovated by Fizer. Now mankind or Dr. Edis want to make the generic and launch it in India. There are significant >> another question before you go on. >> Yeah. >> Till the patent has run out. >> Mhm. >> Does Fiser even during that time think that okay I can go to a mankind or Dr. Ed and they'll make it for cheaper. Why should I make it myself? >> See the cost of production is not material during the patent time.
28:22 >> Right? So they >> 3% 4% >> they make it themselves. But sometimes what happens if a >> local company has more marketing muscles >> they may offer in license >> yes they say we give you we also promote and you also promote >> so very say some therapeutic area >> they'll say let's have them promote our product >> right >> the co- promotion licensing various models exist but coming back to the >> product of what is a generic >> you you can develop the pill >> right >> so that it releases in the same way >> right >> as the innovator's product does >> right >> within a margin of 20%.
29:00 >> Right? >> So if you if it's uh x milligs has dissolved in your body over the 8 hours it should be within 20% of that 8 hours and the concentration also should be within that 20% plus or minus. >> Another question when I buy a tablet in the US >> Mhm. It could be paracetamol and I buy a tablet in India. >> Why do I feel like the US one works better? >> I I don't think that's a uh that's subjective.
29:31 >> The irony basically is what that 40 50% of them are made from over there are manufactured here. >> Yeah. >> Indian companies. >> But yes, I mean regulatory norms are very stringent when you export to US. M >> I mean one thing basically which I know actually when you basically make a drug >> the regulator says that if the impurities are 1 or 2% it's fine for example you say it is 100 mig tablet >> so it is actually the API purity is 98 98.9% or 99.5%.
30:07 Correct. That means what is.5%, these are impurities. >> In US the regulator says it should be 99.8%. In India it's all right. >> No, I wouldn't agree with that. No really >> the standards are the same everywhere. >> How they enforced are different. I think the standard of Indian regulators uh limits on purities impurities are perfectly fine. >> In India side you'll always find in tablets and capsules in medicine overage is always there. Yeah. >> That means it is not 100. It is 100 some mig.
30:41 >> Yeah. >> It is what actually? So that the exipient quantity should be that much >> so that when potential loss is there after 6 months, 1 year, 2 years expiry date comes, it does not get below that particular level where the laboratory fails it laboratory fails it. >> Are the expiry dates shorter in the US? Like if something is not sold for a certain >> there is there's a rigid science behind >> the life cycle of a product and more or less anywhere in the world you have the same standards.
31:12 >> Like I take supplements okay like I take everything from magnesium to sleeping to omega3 and all of that. >> If the bottle is 6 months old versus >> fresh there is a difference. >> See supplements are not well regulated >> right? So you're better off taking from a good brand who has good internal quality systems than rely on a regulatory system to do this. >> But does it deteriorate in terms of efficacy inside a bottle?
31:40 >> Every product degrades, >> right? >> There's something called a stability program we run for every product we sell. >> Every batch we send, >> we retain a part of it to study how it's behaving over the life cycle >> and if there is a problem, we recall it. >> Right? >> That's a quality system all of us. But any drug you buy anywhere in the world the expiry date is minimum 12 months minimum and the same.
32:04 >> So so I mean after that it comes to a label when that quantity becomes less than what basically is being passed by the regulator. Is it right or wrong? >> See it depends on the molecules. In general supplements don't have that rigidity in supervising and quality standards as >> but question is raised. >> I have heard the same question from number of people. Can I buy something from us? >> No, you feel it. >> I'm telling you you feel it.
32:36 >> Like >> you should get it tested analytically and figure out >> what are the difference? >> Like I always wonder like why if it's the same thing why should it be different? >> I I I'll give you one one one this solution for this. >> Yeah. uh change the bottles. I mean nobody should tell you >> that this is a Indian or American >> and then check >> ask somebody in your family right and then check the blind test >> would always be drugs are same and see I mean here they're making in India this called basically I mean pharmacy of the world sells over there good label >> nicely packed nicely kept >> in a right temperature Right. Which is not here actually.
33:22 >> So plus some foreign country. >> You may you may be right. There must be a certain brand you have that experience with >> but as a rule it should not happen. >> Right. >> How big is the generic pharma industry in India? Size wise >> it is uh more than I mean uh 2 lakh cr rupees 60 billion or something is what I heard last >> we have our uh >> 60 billion >> whatever question we want to ask chart GPT he's going to go >> he's got 60 there already >> yeah it's 60 >> 60 billion is three lakh >> 60 into 19 >> 90 >> it's good for you saying 90 >> no it's not 60 actually it's not 60 sorry >> the 60 has come down now because the money we get is in rupees >> right >> so when it was say 65 when it was 80 or so it was 60 billion now we have to discount >> so when you say 60 it is including export correct >> no it's Indian >> only Indian >> generic farmer sold in India >> it is yeah it is less >> yeah yeah >> it is when you >> 30 billion is probably right >> so let's say 60 billion total >> 30 billion India >> 30 billion India.
34:41 >> Yeah. >> And 30 billion foreign exporters. >> Yeah. Yeah. That sounds >> What pace is this industry growing at >> double digit? Double digit >> right now. >> The Indian industry is growing faster >> 8 to 10% right now actually. >> Yeah. And most of this generic farmer market share is between 30 40 companies in the world in India. >> In India top 50 companies have a share of more than approximately 80%. 75 80%.
35:18 >> Top five companies >> top 50 50 top 50 uh top 10 companies would be having more than 40%. >> Yeah. >> And this is a 60 to 70% gross margin business >> must be. Yeah. >> Indian market. Yes. >> And the international market >> it's molecule specific. The branded markets are more attractive. >> The commodity markets give you growth value inflection very fast but the margins are lower >> and EITA is about 22 to 25%.
35:51 >> 20 plus. Yeah. So the Indian market gives you close to 30%. Sure you get more than that but >> that's because you add a brand to the product. >> Yeah. Yeah. Exactly. See, I mean uh it depends upon I mean if you just look at mankind our beta is always in between 25 to 26%. >> Intentionally >> because we just want to grow faster, >> we spend more >> we can increase it. I mean uh bringing bottom line is a mechanism of what spending less using certain things >> but we have never believed in that. M >> we always said that uh if given a choice we'll always go for topline growth >> right >> 25 is fine we happy with 25 26 >> but uh not compromise as far as the growth is concerned because what has made mankind >> and when people say India is the pharmacy of the world they mean by volume they don't mean by revenue >> volume is what 60% >> 60% of the global >> but revenue is like five six% >> not five I think 15 or So >> huh >> by value >> you say approximately 5%. Or 5%. Yeah.
37:03 >> Why is that? Even >> because we are in the generic industry. We are not the pharmacy of the world. We are the generic pharmacy of the world. >> We sell generics largely and there the pricing is much much lower >> over there. I mean who makes the money? >> The pharmacyes. >> Yeah. >> Yeah. All grains of the world. So in the US the innovator price >> if >> it's 100 >> post patent expiry if there are more than five players the price falls to north of the discount falls north to north of 95%. Can be sometimes 1% 2% of the innovator's price. So that's the value difference we play in that part of the world whereas they are on the you know premium person.
37:50 >> When you're selling generic also there's a brand attached to it. >> Yeah. Even for generic >> what our research was saying is say for example Dr. Eddies in many companies would have tie-ups with doctors and specialists in tier one cities and mankind kind of penetrated the tier 2 and three cities. How big a part do the doctors play in the value chain of figuring out what pharmaceutical company do they buy their generic drugs from? In [clears throat] India first of all uh you're supposed to understand that I mean u 95% products are branded generic 5% >> for example >> take any for example uh you take >> then there's a a toz there's a fate there's a 20 other brands method 20 brands are there you take uh moxyan cbrs or agumentin or somebody else 20 brands are there right >> the price points are different something is a bit uh 20% % expensive >> based on what?
38:53 >> As per the company's philosophy and policy. >> So say for example mankind has a drug for I don't know headache. >> Okay. >> And Dr. Eddie has a drug for headache. I'm a doctor in Goa. Now how do I decide whether I prescribe your drug or his drug? >> Totally. I mean uh it's basically relationship based >> uh based on the salesman who goes over there. >> Right. >> Right. talks to him, convince him to prescribe and it's all a one-to-one relationship and the reach and the prices and uh see I mean >> so these are pharmaceutical reps >> absolutely >> which you both employ >> thousands of them >> thousands of them [clears throat] >> I think we have thousand we have 10,000 >> we have 17,000 >> 17,000 >> when this man thing came so philosophy was that we'll not follow any pharma company >> top down approach will not be here right >> why should I go to bigger cities >> right >> I have no resources why should I fight in their battlegrounds where there are strongholds >> we started bottom up >> right >> when you go to your village and sell your product you are supposed to understand the ecosystem how much patient will carry in his pocket how much doctor will charge how much you can buy >> right >> keeping everything in mind >> we intentionally kept our prices 50% 60% 40% more affordable >> then best of the Mhm.
40:18 >> So who gets what share? Say you sell a drug for 100 rupees. >> Mhm. >> In tier two town. >> Mhm. >> Okay. Tier two. >> Same drug. I will sell in bigger city the same price. >> MRP. >> Okay. >> Whatever MRP is there. >> Mhm. >> If a villager is buying or a big city guy is buying >> the price is the same. >> So >> no difference. >> So your retail price is 100.
40:41 >> Mhm. >> How much out of this 100 goes to say distribution margin to employ these 17,000? 10%. >> 10 no who who employs what retailer >> who employs what employ 17,000 >> you employ 17,000 out of this 100 rupees >> how much 100 rupees is what you're getting when the pharmaceutical guy sells it. >> Yes. >> Yeah. Then you just just take it like this 100 rupees is the MRP. >> MRP. Okay. >> That's a better way of looking at.
41:07 >> So in this value chain how much goes to the pharmacy? >> 20%. >> Okay. >> 10% wholesaler. >> 10% wholesaler. Doctor, >> no doctor distributor gets >> 2%. >> But why does the doctor then pick one over the other? >> Relationship. >> What? What? Doctors >> relationship meaning you don't give money but you give something else. >> No, we don't. It's like for example, >> it's illegal to give >> it's for example in our case when we started man nobody from bigger companies were going to these doctors >> right? They they were I mean nobody thought that one should visit them >> right? So we went over there, we convinced them we are affordable, we are good people, >> right?
41:50 >> They prescribe it. I told you FMCG. >> Why do you tell me one thing? Why do you why buy SURF and not Nirma? >> Yeah. Why? Why a GI is being sold more in smaller towns? >> But we're almost talking why does a doctor sell Nirmma versus Surf? >> See the point basically is what doctor is a human being. No. So >> I mean somebody goes twice a month to you >> wait for you meet you >> uh requests you it's all about that only >> but what is the balance okay doctor let's assume nothing pharmacy 20 >> distributed as what takes from you >> yeah 2 3% >> he takes from you to the pharmacy >> you know he does to the >> I mean 100 then 80 then 10% less is 72 then 2% less is >> see this homeer delivers to thearmacies.
42:40 He has a group ofarmacies he'll send to. >> Okay. >> This guy is a much larger territory. He'll keep the stock >> take it here and then this guy takes it here. >> And distributor makes 3 4%. >> Yeah. >> See, distributor is like a depot or CNFK and forwarding agent, >> right? >> Yeah. Distributor is that >> stockist is wholesaler. >> I'm a wholesaler, right? >> I get 10% I supply to every pharmacy. >> Sometimes I give deliveries to the same pharmacy two times a Two times a day, three times a day. I have my boys a supply, >> right?
43:11 >> This is my job. >> And distributor for doing this job gets how much? >> 10%. >> 10%. >> Wholesaler. >> Wholesaler is distributor. >> Wholesaler is >> wholesaler, distributor, whatever you call it. >> Three three things are there. Okay. >> CNF is a >> CNF, Depot, supertock is whatever you call it. >> So out of 100 you are left with 70 >> 68 66 or something. >> Okay. And then then the 60 you have to pay the salary of these 17,000 pharmaceutical reps.
43:41 >> They're managers, they're senior managers and everybody in marketing side every everything. >> How much does it cost you to make the drug? >> Uh depends upon I mean for example if I say that uh if the gross margin is say 65%. So rest you can 35 25 to 35 rupees to make that >> plus don't forget that apart from this there are certain schemes which we which every pharma company keeps running actually >> like Apollo I buy from Apollo they have some points and all that >> no see since the coming of onlineies >> we started giving 10% 5% kind of discounts >> right so the same customer now goes to a medical store right and says give me a discount so he demands from the company how come right online has a different model so companies started giving 10% and 5% and 15% kind of >> right schemes to these medical stores >> funny story when I was 17 years old I started a pharmacy store >> yeah I had two shops one pharmacy one uh you must be quite >> aware but I'm talking 22 years ago >> even 20 years back.
44:57 >> I remember even back then the highest margins were in some of your products like condoms and stuff. >> We we we made everybody happy. >> Yeah. I used to pay rent to be displayed like you used to pay 10% of my shop's rent. My rent was some 10,000 rupees. Like I think 2,000 rupees used to come from displaying. >> You always been like that. >> Give [laughter] to everybody and make everybody happy. See, I mean point is what you want to grow very fast. You're supposed to really capture the imagination >> of the consumer customer. How can you do that?
45:28 >> Yeah. >> We thought like that >> in this I have a question now. Is online pharmacy a good business idea? >> I'm speaking up. It's still not I think uh >> will it kill retailies like Amazon did? I'm not sure but I think um certain category of products will they in this quick commerce people are delivering medicines now the exact >> is that like they have a doctor call you 80 rupees doctor consultation and then they send you the medicine is that legal >> I mean this basically is curving the rule actually um as per the law without doctor's consent prescription you cannot sell >> so for example if I go to on online pharmacy and says that I need this. So they have a doctor >> will talk to the patient write the same medicine it >> yeah but I'll tell you why it's legal online consultation is legal so what they are essentially doing is a online consultation to >> prashad for example I'm a doctor I have written you right you go to a online pharmacy then >> so if you have the prescription just upload it they'll give it to you then send it >> so to our audience you think is this an opportunity is this an Is retail pharmacy or online pharmacy a business opportunity that's worthwhile?
46:53 >> No. >> You need to have very deep pockets for that. Just think >> uh if you're selling online, why somebody will buy your product? Are you giving cheaper then? >> Maybe I'm in their area and I can give them >> the the online thing is cheaper than a pharmacy medicine. They give a discount. >> I'm a nearby chemist. I can give you this. I'm one phone call away because this local chemists have become very active now >> right >> one phone call away they supply the things which was not there >> and they give a discount as well >> but phone call is still an effort like quickcommerce you call a kirana shop also he'll send you but people go on the app and press the buttons is easier to pick 10 things than talking to somebody >> some people I mean at a different level I mean small scale have started this kind of apps >> I'm not saying I mean like for example example any any startup >> they have started this >> Tata 1 MG is biggest now >> they are big companies but I'm talking about I mean at local level as well small RAM agencies have for example I'm just giving a name hypothetical name >> uh 50 camist and he has started his own and he is basically I mean uh spreading his app everywhere >> right >> this is also happening >> but you're saying there's not really a big >> point anywhere else else in this valueain distributor, wholesaler.
48:18 Are these businesses a 25 year old can enter or probably not? >> They're all very mature businesses, right? >> Well established, >> right? >> Difficult to disrupt them, >> right? >> So there's not much uh >> technology if you basically online business can happen but there you require huge amount of capital. >> It's not a 25 year old job. Tata MG 1 MG is still not profitable. >> Raised 800 crores. Yeah, >> just think that kind of capital.
48:45 >> Think from a different angle, >> right? >> Don't come in this particular line. For example, >> I'm a young guy. I'm I I mean I know this technology it saving. >> Uh I start selling something else >> which is not medicinal for example uh supplements >> for example vitamins >> but that's too crowded now. >> Absolutely everything is too crowded till some somebody breaks it cracks it. How can they break it? For example, our see nowadays you must have seen all of the magnesium has become flavor right >> 5x everybody puts 5x 10x 20 >> but somebody started fast >> I mean somebody started dispersible tablets because now cost is not the most important thing in this genzi crowd I mean for example this youth >> if if if somebody's concerned about his health >> he wants a flavor he want a good-look >> uh tablet capsules I mean see the Point is not uh bringing the same thing in the same packaging in the same manner in the same formulation.
49:50 >> The point is making it very attractive in such a manner that you end up buying it. >> You become a brand. >> Yeah. You become a brand. It's like that only >> like in a way boldare kind of started from that. >> Yeah. >> That's example. >> Are you interested in buying bold? >> No, we have our own man force [laughter] >> right. We we got many aparties of buying different condom brands but man force is man force >> right >> nice name I think man force >> my brother is very good in keeping names >> he's very mankind he kept I'll say >> 80% names he has kept unwanted >> it plays a big part no >> huge >> the name >> recall very recall >> like Dr. already the doctor changed everything I think.
50:39 >> They [laughter] they they have some very good names. >> Homies. >> Yeah. >> Yeah. Homies is amazing name. >> Is there a science to it picking names? >> It should be easy. I mean uh a fourletter word is always >> there are usual brand rules. Easy recollection rolling of the tongue recall value. >> The score >> on the basis of it should not be too close to >> on the basis of name of the molecule.
51:04 Right >> like this only >> right now hospitals where do they play a part in it? How many doctors are individual in India and how many are behind a hospital? >> I don't know the said [clears throat] most of them are individual. See I mean after >> even hospitals there are people who have practice within the hospital >> right >> so they have a control on what's prescribed >> but after the coming of Apollos and max and 40s and narral chains >> yeah I'll say good quantity of uh doctors are attached with different >> hospitals >> and um there's a change in the mindset of the consumer and patient as well that if I go to a single clinic >> and he says no go for eye checkup as well I'm going for a fever or hypertension or diabetes go for ENT >> so instead of going over there if I go to a multi-p specialy >> hospital I get one go all the things right so I feel today uh approximately 15 20% doctors would be attached with hospitals yes they practice separately as well as prasad said they're saying 15 20% of doctors and how does a hospital figure out which brand of drugs to sell?
52:23 >> Again meeting those do doctors? It's their call. >> It's pharmaceutical reps again. >> Yeah. Yeah. Again. Yeah. >> Even in a hospital >> they have institutional but they are different rats. They are a bit more smarter more managers >> specialy. >> They probably pay get paid 10 lakhs a month. >> No no nobody gets nobody [laughter] >> to to get 10 lakhs. What kind of a sales you're supposed to bring every month? >> I know but if you have 22 month margin >> PCPM just curious >> our PCPM right now is >> overall for 17,000 >> 7 lakh.
52:58 >> So PCPM is per capita >> per medical sale. So he's selling seven lakhs a month >> each rep >> each rep on average >> average which is a good number. >> Some would be 30 lakh some would be 50 lakh >> right >> but some would be very less >> right >> but seven lakhs is quite healthy across the board. This is a digression. This is not related to your industries. I work in private equity. So a lot of my friends in the US especially are feeling very gung-ho about hospitals in India.
53:29 >> They're buying many small hospitals, aggregating them, putting a brand behind them. You've seen Max money pulse IPO is coming up. >> These [clears throat] are also friends of mine, the hospital owners >> and they have multiples of 80, 90. >> That's my question. Is that justified? If you buy a hospital individually on the something in this locality, you're probably able to buy it at five to 10 times a bitter. >> Yeah. >> But once it's listed, it suddenly has a multiple of 80 90 once a brand is attached. How do you see that business?
54:02 >> See, see to justify 8090 just calculate how much they have to grow at. >> Yeah. >> The the market is underserved. No doubt about it. But insurance is well de not well developed. The people coming in largely are under the government schemes which puts a cap on earnings. So for growth you have to keep adding beds, adding beds, adding beds and you see that everybody says we adding thousand beds adding final >> but they have this logic know they say in the US for every three people there is a bed in India for every >> it's an underserved market I agree >> but it's it's like everything else it >> then to a unorganized >> or a one of one hospital which is not really running at the best level excellent level >> right >> I mean they will bring different processes >> they will add some pharmacy they will negotiate better prices of the pharmacy with the companies they will negotiate better prices with whatever is being used in the OT so they can they can bring some kind of excellence over there >> by bringing systems at the same time >> uh once something has a brand attached so validation is always there >> right right >> so uh big doctor can be brought >> the doctor who's who has a name you can be visiting faculty as well >> right all sort of things can be done and uh that's a flavor right now right because you start controlling not only the pharmacy doctors everything you start controlling right at the same time what happens all all the government schemes which says that you're supposed to go for a one day admission then you get this right right they get the benefit of that as well so better uh I'll say better management But do you think if I'm a stock investor or I'm a private equity fund, do you think I should buy a hospitality?
55:56 >> What's your answer? You know it very well. [laughter] >> People are buying. >> Let people buy. But what is your answer? >> I I don't know. I'm conflicted because 80 times sounds bad. But these guys are growing at 20%. >> But does 20% give you an 80 multiple? 20% >> consistently even thus >> 20 25% >> I don't know the equation but I I I >> see the multiple one year is down [clears throat] from 80 to >> 60 >> 64 I >> I think it's a it's a very difficult game to scale because it's a real estate play at the end of the day >> it's a huge amount of >> the line he said is that India is underserved is absolutely correct >> I mean if you just look at the the difference between a hotel Right? Rooms all sort of thing, kitchen, other things versus a hospital, >> right? How much money >> per room charges and again the point again I I forgot one point.
56:59 >> If I take a deluxe room, >> so my prices in OT prices everywhere are different. Yeah, >> I found that I was in the hospital recently. If you take the best room, >> you pay more. >> Double. >> Yeah. like from tablet to injection to everything is doubled. >> So those thought of those sort of things are there. >> I mean if uh >> the other thing is hospitals the demand curve is not very elastic.
57:28 >> So if you have a doctor you'll go back to him again and again. >> Yeah. >> And if he changes his hospital you'll go to him in other hospital. >> Great. >> So but hospitals have really changed this particular uh trend. M >> some people have done it. >> I mean every time you cannot bring a buy a new hospital and bring a best doctor not possible. >> This hospital if you take any chain the hospital which delivers the maximum revenue per bed >> will be the one where the stars are >> the star doctors.
58:02 >> Yeah. >> Or the founder is theirs. So for example you take Naran where Dishett is there you'll get the best. We'll take the max. >> Actually, they are not expensive. Strangely enough, Narana is still at 35 times. >> Not expensive, but that's where the revenue will be higher. >> Yeah. >> Uh Sam, just give me that macha bat. No, there's one fly. I'm going to kill it. >> Yeah, it's >> it's annoying. >> Flies are difficult to correct.
58:26 >> No, with that mosquito bat, I love doing it. >> It's a hobby of mine. >> Mosquito [laughter] is relatively lazy. The fly is very fast. It's almost like it's almost like a recreational activity for me. I'll go chasing mosquitoes and killing. >> My son gets up at 3:00 in the night and starts catching. >> But killing them is satisfying. >> Mhm. >> No. >> So, you're an animal lover? >> Animal [laughter] lover. [music] >> [music] >> Okay, tell me this. Why is China first? Okay, before we go to China, we'll go to US tariff.
59:18 >> Tariff on generic drugs apply from April 26. >> No, >> they don't apply. >> There's no tariff on >> No, no tariff on >> Essential Commodity Act. Okay. So, China and India are at par >> if they are selling in America. >> So, there is there are innovator >> right >> products. >> If they made in India, there's a 100% tariff. >> Thank you. >> Oh, really? >> Yeah. >> So, if you innovate your drug in India, you pay >> No. If you're selling it to the US >> and it's an innovative drug, not a generic drug >> and it's not manufactured in the US, it's manufactured in India, >> there is a likelihood of a 100% tariff on >> so this affects our CDMO industry, the contract development manufacturing.
60:03 >> Yeah, I think we'll come to that CDMO. That's also interesting. >> Yeah. >> And government has started thesearmacies which are government. >> Yeah. Is that a big deal? It's in the long run if it's going to erode the brand anything it's very healthy for pharmaceutical industry. It >> it must have impacted a lot in smaller towns. >> Please >> uh uh we if the growth is say 8 to 10% >> had these Jani would not be there the growth would have been much much better.
60:39 >> Yeah. >> Yeah. >> How much are they selling? Chashadi >> at a very low price. No value much not so >> the point basically uh >> I feel I mean not more than I mean uh it's a rough kind of estimate uh 4 5,000 >> 2,000 >> huh yeah yeah yeah even lesser than this the reason is there >> but when you sell something at a very cheap price >> to run that gen oi >> is a problem you look if your daily sale is say for example 2,000 rupees >> what will you earn earn out of that you need to have at least 50,000 1 lakh rupees sales daily >> then you earn 10%.
61:22 >> And generously the profit of margin for the person who's running is also very low. One the MRP is low the second you sell use quantity but the value per se is less and percentage to that guy is also less. >> The Jan Ashadi stores are being run by capitalism. Is he looking to make a profit or is it like a government scheme? >> The government is not running that only. The government has given to somebody, >> right?
61:51 >> Somebody who is a businessman. >> The businessman is trying to make money from >> per month per per month. No. So per day is how much? >> 5,000. >> That's point actually. >> So they won't be able to survive your >> quite difficult. I mean and sometimes the the complete uh I'll say variety is not there every kind of medicine is not available supply chain issues are there also bit socialist leaning no what do you make of that if government starts capping the price of your drugs >> they are capping >> the caps are there >> they are capping >> even though you're selling at a percentage of what it sells a product >> yeah even then they they have a way of calculating what maximum we can make and they give us inflation every year. But there are the category of products which are listed as NLEM.
62:52 >> Mhm. >> National list of >> NLM N >> essential list published. These are all controlled prices, >> right? >> It's not a big list, is it? >> 300. >> Yeah. 350, 400 kind of >> essential drugs, paracetamol, cifax, cyproloxine, the normal, I mean a drug which is being used by everybody most common, >> right? >> National list of essential medicines. >> We were reading somewhere that China is suddenly winning a lot of the generic contracts, >> not genomics, but innovation.
63:29 innovation. >> China's story is >> what are they doing? >> Okay, they're the number two in the world in terms of innovation. >> M >> 29% of all new drugs are now I think in cancer are coming from China. Um 70% of the biologics which novel biologics ADCs are coming from there. A very large number of the bicep specifics are coming from there. They've overtaken everybody else except the US from innovative medicines.
64:08 >> How this is a long story. I think they started about 2015 or so. But um um I let you murder the guy first. [laughter] Mhm. >> So, China as you know they're a force in >> about eight or nine industries. They >> choose to become leaders at [laughter] >> you'll never get a fly. Fly is not easy.
64:41 >> So, uh they did that in biotechnology. >> Yeah. So there's a national fund, there's priv non- relative financing, >> the stock market recognizes the value of innovation, there's a home market >> for innovation. >> So they create an entire ecosystem for innovation. >> How do they do that? I've seen them do this in so many industries. >> Yeah. So they have their playbook for this. I think they get talent back. This what they call as sea turtles program or something.
65:11 >> VC venture capital funding. H There is u >> this is crazy. Huh? [laughter] Fly is not easy to kill. >> Mus are different. >> We'll keep it here. >> Let's see if the fly is smart enough to recognize the weapon. [laughter] >> That's your hope. >> It's very very irritating. >> No, my wife does this with mosquitoes, but fly is impossible. Yeah, there's right. It's having a salad.
65:48 Wow, I'm kind of like starting to vouch for the fly by now. [laughter] >> And they also have the ramped up research in their universities. >> So the top universities publish a lot. The largest number of scientific publications are coming from China >> now. And hence they've built all elements of the ecosystem knowledge through universities and research institutions risk capital through public funded VCs and you know government funded private equity. Uh I mean they've created these funds where the private sector and the government collaborate and co-invest.
66:32 >> So there's all kinds of incentives for entrepreneurs to really invest in innovation. >> What does India have to do to compete? because this is new for them, right? >> Yeah. Yeah. So, I I would say the government has realized that this is a war they want to win and they said this explicitly in the last budget. So, they put some money aside 10,000 crores fund I don't know what the fund is called but there's a government fund 10,000 crores.
67:00 Then there's a announcement that they will form a fund of funds which they will give to people like you to invest in companies. M >> they have a directly funding P R >> um public reserve for innovation something P fund which they're funding innovation in companies >> uh small amounts of money what is it pardon me >> show it show >> bioshaki yeah that's the fund but there's also a larger fund $100,000 100,000 crores >> um >> so it's a venture capital fund for startup >> yeah So part of that will go to bio fun >> and then they have something called the research innovation program something >> which also they're giving direct money to companies for specific programs.
67:49 >> If you are successful you have to return one point some eggs otherwise it's you know written off so lot of work is going on but not nowhere close to the scale of these companies. See the point point is what I mean when you basically enter R&D >> kind of a domain >> right >> the chances of >> uh success [laughter] >> are not like I mean you're very sure that some kind of a success would come >> so a company needs what or a scientist or a university need what grants >> some kind of a grant some kind of I'm an ecosystem some kind of a help >> and help not for one year. It's not like for example now you have started and okay fine it will happen. You need to consistently infuse I mean some kind of a thrust over there, money over there, help over there and some kind of a support system that if you succeed we'll miss more like it happens in any uh startup what a venture uh but even Trump is reducing this right >> Trump has reduced a lot of funding for the public research institutions.
68:58 >> Yeah. Yeah. Farmer years for farmer years they never gave any money. >> So they were funding public research in universities as well as there are you know national institute of cancer and it >> those were all doing a lot of research. M NCI National Cancer Institute >> used to spend $40 billion every year in research >> right >> so the scale is very different >> right >> so China is the only country which moved so fast >> and they've overtaken Korea Japan Europe they're now next to us in terms of >> they do this a lot with many industries Yeah, they are the people who are actually leveraging the capital system, capitalist system to its fullest.
69:50 >> Yeah. >> Being a socialist and communist country. >> No, they're they're exploiting the, you know, capitalist system much better than anybody else. >> Right. Do you think that has to do with the non-election non bipartisan nature of governing the country where they can make a plan for 20 years? 100% why not I mean if you just plan something like R&D >> where uh I mean if you start today I mean chances of success are after seven years >> Mhm. Right. In five years elections are there and some other government comes.
70:30 >> But Rajiv, >> I'm just giving this is an excuse people say if any state in our country started a good program the subsequent governments have followed through they've not disrupted it. >> Yeah. >> Very good policy. You take our own state when it was a combined state. Chandra Nud was the master. He put the plans together for states which are exceptional. I mean these are guys who have done good. So if a politician does good it'll make a difference. You look at the API market good politician bad API market or any other market wherever I mean for example if local industry is not being supported and some other country like China dump the goods what happens in any any any feed it happens. So some kind of a support some kind of barrier to entry is required.
71:19 >> Yeah. But you know what I think we should learn from the Chinese >> from >> from the Chinese. These guys have achieved tremendous success in everything they went out and >> I'm actually reading a book right now >> which is the biography in a way of Deng Xiaoing. >> It's about the transition of Mao to Deng. Mao was like cultural revolution fully fully communist >> and Deng came in and he kind of like converted it to some version of capitalism without calling it capitalism.
71:50 >> If I have to >> market system whatever >> if I have to pick one lesson >> from what China did right is every state every mayor competed with the mayor of his neighboring state >> the mayor was in a meritocracy. If he didn't do well he wouldn't progress. >> Correct. the mayor of Shangghai you know becomes goes to Beijing only if he does a great job in Shanghai. So the guys >> the same thing here >> we should I mean there are many ideas we can take from this whole uh you know that the way the Chinese have moved in the last 15 20 years it's mindboggling in every field not just our field you take EVs you take uh uh >> I was there in China I mean Jane last January >> mhm >> and uh I was totally amazed to see kind of ecosystem they have built up >> I mean I feel uh the day is not very far >> I mean he will agree with me that u definitely won't like us.
72:44 >> Yeah. >> Yeah. They're not competing with us. They are competing with the US. >> Yeah. That's sort of a speed and I'll say support and mindset and talent. >> What he said in the starting that they brought talent here. But why talent would come >> from us? Why you will leave? >> Because if you if you give that talent a chance to become an entrepreneur >> and government supports you in that it does not happen. I mean some kind of I'll say some kind of a support system is required uh some kind of a backing is required uh money uh resources and also uh I'll say uh that I am with you >> yeah I mean uh you're doing good job for the country >> when when something of this sort happens I mean these are really very impressive things I mean he carries that particular emotion in his heart >> no I mean I I I a great admirer of what they've done.
73:42 >> You see the quality of the stuff in in our own industry. >> Yeah. >> In 25 years ago when we started seeing them come in >> Yeah. >> with low cost API low cost said these guys how do they make money? How will they survive? They'll go away from business. This is what we were saying. >> Prasad how you think that API industry of India has been killed by China. >> They've not been killed by the way. I'm I'm not going to buy that argument also.
74:03 I think Indian is still Indians still lead and I'll tell you why we lead and how we lead. They they're not playing the API game. They're selling these cheap intermediates to us. We convert them into API. We make more money than them. So that I don't think is a problem. The problem we we saw is we were we didn't read them well. They were selling us this low cost materials. We thought, oh, these guys won't survive.
74:25 The government is subsidizing. When the power prices go up, they will run out of business. But they were playing a long game. They were just playing one by one. They didn't want to compete with us on the API generic API or the generic business. They wanted to go to the highest end of the value chain for which they put all the blocks. They put a CDMO business, they put a chemical business, they put a all the petrochemical raw full integration from here to innovation. They own the whole chain.
74:57 That's I think stupendous if you see how they built it with such vision and such uh consistency, persistence and long range thinking. >> Yeah, they are smart people actually. No, no less people >> aggressive very entrepreneurs are very strong very fast >> very >> I think because that they have the upside. I feel like there's no fear [snorts] because at the end of the day growth comes first everything else is secondary >> and B the fact that they're competing amongst each other not just money allocators or risktakers which are the entrepreneurs in society but also the governments each state government each mayor I think changes everything >> yeah and you know if you look at the people in government >> so you know in our system I don't know the smartest people the IS people are very smart they are but here you see them so they're so sharp >> you don't uh you know if you compare them with the private sector >> some of our best brains go to private sector they don't go to government but here you see the best guys are in government they think >> why is that >> I think the system is very you know recogniz >> because it's not because it's pseudocommunist proximity to power is the highest value it's not capital >> I have no idea really I I don't know but I was impressed by the quality of think among the government people I met there.
76:20 >> So my experience over there in China was very different. I mean so I met I mean number of people I mean say in the quantity of say 25 different companies some startups and uh in 50% of the cases >> their background was US >> studied over there >> 100% Americans look like Chinese >> they're Chinese they were Chinese and they were called they came what was the incentive incentive was that uh we'll just give you resources his ecosystem and we'll applaud you. You're a Chinese guy. We're proud of you.
76:57 >> They also have monetary incentives to come. done a lot of monetary reason I mean and those people those who have basically worked over there worked in under those basic scientist in Harvard and other Stanford universities they come they start and if they succeed I mean initial money is being given if they succeed come government gives them huge money >> buys their product helps in every step see for example I mean if it's not only the resources and ecosystem if for example Minister says I mean takes your name >> and this is Dr. already done fantastic job right call you a stage on a program just few lines how much moral boosting it is for the whole science science community >> yeah but also >> giving you some example I'm talking about the human side actually >> but the human side is not the whole story they're giving housing which is as good as western countries living quality of life they're giving >> apart from everything >> resources >> all that matters also if a guy comes here he can't get a house he can't buy a house for 10 years you know why are they going to come here you need everything just patting the back is not enough >> that's when I said I mean one point of program should be there >> that for next 15 years 20 years this has to really happen >> then we'll become some see in which which year China came in R&D side you know it very wellift how >> 2015 >> now >> 10 years >> now to be to give them full credit >> they also they benefited a lot from the us not only just the talent they also do all the big deals they don't develop product market them globally apart from China they get fizer J&J these companies to do deals with them 50 billion or so last year's deal making in uh from China and all the global trials are coming from China now so in a way they're leveraging the US >> I give one example what I said I'm not saying anything out of anything else without having some some kind of experience Recently one of the scientists had joined uh from Belgium. He used to work in Jonathan John. So his name is Dr.
79:06 Anel Call. Right. >> He was uh >> it's a good recruitment. I I looked at it. The guy was very impressive. >> Yeah. Tell you honestly. >> Yeah. >> And see this was a guy who basically was working in Belgium. Modi went over there >> and in one of one of the seminar he was there. He was working on infectious diseases. >> So Modi said you must come to India >> right? Mhm. >> And must come to your Indian must come to India.
79:32 >> Can you believe >> he left the job? Come to India head infectious disease uh department in India for 3 years. Wow. >> I'm saying that. >> Yeah. No, Modi is very good but Modi is also one individual. >> I'm saying that. Yeah. >> I'm saying that. I mean, >> how does it trickle down lower down in the bureaucracy? Now I'm saying that if the same kind of examples other big guys can take it's never only the resources never only I mean I give you resources I give you everything then I don't don't ask you I need to ask you I need to I mean if I come to you and take your name and see what is what's the progress the big guy is asking >> something happens >> it's a combination of things >> we all need seek >> validation I agree with you and I would build on top of that. I feel like you have to eliminate fear.
80:26 >> Yeah. >> India has too much fear in entrepreneurship where everybody's worried about this agency, that tax, this red tape >> that has to structurally go away. Like you have to be like okay net net is this helping or is this hurting in sure there are bad actors who should be punished and all of that but the question should be net net are they inculcating fear or are they encouraging industry to do more that is what I'm saying >> yeah I mean if somebody has done a innocent mistake yeah understand don't don't go by the I'll say the lines see the intentions >> I mean we all understand all these things. Smart people know it very well.
81:11 >> We are planning to go to China in June. We are hoping to do what China did to somebody in India. >> China. Let's see. >> It's an interesting place. >> You It blows you away. I mean on one side we compete with China but certain qualities of China must be learned. Brought it here. What's wrong in it? >> No, you should learn always. We licensed a molecule from a Chinese company launched it >> and you paid a huge money for that.
81:38 Yeah. >> Not a very huge money >> but you know it's it's already a 100 crore band in this year launch year of launch. We could never achieve such results. >> A lot of Indian companies are going over there and doing a license deal with those Chinese companies >> and they're very aggressive. >> Yeah. >> You know one thing that really surprised me I'm moving from generic to an ancillary thing. >> Mhm. is Aayush and Aayurveda. How is it so big? Is it 30 billion?
82:09 >> No. >> How can it be that big? >> There there are certain companies. >> Uh I think this includes the doctors. >> Yeah. >> It includes the people giving Ayurvedic massages. It includes live [clears throat] 52. >> No, no. This this also includes only I mean unbranded ji booties as well. >> Yeah. >> Uh like for example other companies sell um lot of companies are there.
82:45 >> Yeah. Plenty of things are there. >> Chilig and this is growing by what percentage? >> Live 52 is a very popular one. And I remember cuz my dad used to take >> liver health liver extract actually. >> Yeah. >> Like back in the day like 20 years ago live 52 was everywhere that Himalayas live 52. >> My grandmother used to drink the syrup. >> I used to think there was alcohol in it or something. >> Yeah. Why is it so big? Why is it 30 billion? What are we missing?
83:16 It's as big as the generic farmer industry of India. Pharmaceutical industry of India. But if you just take the pharmaceuticals versus the ayurvedic pharmaceuticals, I don't think much smaller. Yeah. Much smaller. >> You basically talking about as a whole >> and it's growing at 17%. >> Yeah. Yeah. As a whole, >> it's growing 7% faster than farmer. >> Uh I tell you honestly, you you'll also find lot of uh growth you'll find in uh supplements nowadays. A lot of growth you'll find in uh vitamins and minerals.
83:48 Why? Because after covid the mindset of people have really changed. Whenever something uh alopathic is there pharmicide is there >> it is to cure >> when you want a longer kind of I mean say immunity longer kind of a for example I'm allergic to this I get cold then I switch towards these things >> right >> so they become a kind of a lifestyle kind of a >> drug for me >> I keep I'm taking le 52 I'm taking it all right >> yeah I think the the right comparison reason would be to not compare them with pharmaceuticals >> but compare them with wellness products >> right >> a lot of them are you know wellness you you take everything 52 you take various things like that >> I'll actually add longevity and wellness under this yeah these are all preventative >> right >> yeah whereas farmer is curative >> there are some things like vitamins which come in as supplements but >> but do you think this is where the opportunity is for someone young starting a business >> good idea >> cuz it's growing at 17% It's a it it is a it's a place to come.
84:55 >> But what should they build in this? >> Uh what should they build basically is what I mean if you just look at the Arida side >> uh a do you believe in it? >> I don't. >> You don't? >> I don't because as a company we have committed to evidence evidence back >> turmeric and ginger. >> Yeah. If we we've done trials with turmeric we didn't see significant >> ginger. Yeah. Those are maybe preventive but anything as a medicine I don't know we don't >> no I'm not saying they work as a medicine but these guys are claiming that preventing the disease is more important than treating the disease.
85:32 >> Yeah. So is there any control trial which shows that this is better than not taking it. >> Turmeric and knowledge should be there. No >> it's all you know anecdotal. >> Yeah >> there's no control study. >> So we sell and we believe >> right. >> We sell and we believe actually. And um >> what are the products you sell? be shilit, >> ashwagandha >> and uh neutrin tonics right there are neutrinonics for liver >> lot of things we sell >> but what would you say when he says there's not enough evidence >> I'm saying not enough evidence to back the claims that are being made I mean see I mean there's anecdotal evidence there's history there is mythology all of that is there >> the original medicines came from plants only right >> yeah yeah >> they came from plants and I'm not think they have not wor they don't work but I cannot commit to that saying that you know this is backed by evidence >> so my argument basically is what I mean if uh we go to a clinician >> and if he uses it >> and says if it is effective then only we'll use it use it again >> and these are I mean time- tested >> we not bringing something novel something new >> these are being I mean time- tested old medicines >> right The problem basically lies in aruida is that there are less I mean it's now very clear testing methods >> the purity >> is the issue actually >> uh and lot of time when uh regulatory is not very very strong >> uh there are complaints of uh I'll say >> uh adding certain other things in that for example in this uh in some of the drugs lead has been found >> heavy metals >> heavy metals have been found. I mean if somebody brings a very pure kind of a thing >> standardization standards >> I mean right standards really happen when you say aruveda >> right the purest form of arudda is being exported >> I mean >> what bas see what what is basically is arua the leaves and uh branches and trees whatever is there >> so what is the most pure form versus the rest of the material left >> so when from the rest of the material you bring the extract and sell it on the name of arrived right >> the best stuff is it's like tea the best stuff goes out >> yeah yeah yeah same same like that actually yeah >> but why is that if you in India all these tiny brands which are coming up Ashwagandha Shilit and all they charge 3,000 rupees a bottle >> they sell like that >> yeah then why not keep the best stuff so >> point is what is a big market you look at the big market look at the price they get the profit they get I mean always I mean uh things follow money actually >> you're saying there isn't a big enough market of people paying 2 3,000 rupees for a bottle of chili that's >> so that's why it gets I mean everybody says it's a shilit it's a commodity >> but somebody I mean uh put a brand on it give a uh right marketing and says that we do do it like this only a purest form it comes from the Himalaya >> I mean you need market it very very well >> but you're getting the export stuff or are you getting the leftovers >> we we are a 85% India company so our focus has always been India so what whenever we export something two conditions it has to have some kind of a I'll say uh difficulty in manufacturing for others >> right >> it should not be a very generic product we don't want revenue from that place right >> we want that uh longevity we want uh profits over there. We want some kind of respect from that side. And that's one reason we have chosen this path.
89:20 >> Right? >> We'll not sell uh journal products. We don't want top line from that side. >> Right? >> If some complex product is there, difficult to manufacture product is there otherwise. >> But you're saying this 17% is right. How big of mankind's business is this part? >> Minus. >> Yeah. >> Minus. We we just going crazy. >> Yeah. Going good. >> Not crazy. in Aruveda I mean uh it's a slowly accepted kind of a product around centuries you're selling something 3,000 rupees so how many people would be buying 3,000 rupees premium class no >> like 10 million people in India 10 20 million >> even less than that >> and out of those I mean how will be how how many will be convinced and then you basically send these so but what we basically do we send these products we want a paper from Aruvedic colleges. You try over there, you give us some kind of a paper >> and then we'll sell it. It's a long process.
90:24 [music] >> [music] [music] >> government was planning to make Aayush doctors like normal doctors or something like that, right? It's a topic I don't want to talk about.
91:08 >> No. Do you have a view on it? >> Yeah. Good. Okay. Why not? If a chemist can give >> medicine to a patient, why not? Hey, are you doctor? >> He has some kind of a knowledge. Plus uh they can be educated as well through online courses and many doctors are ready to give this kind of education. So I have when I used to work in those days BMS doctors every kind of a doctor used to practice >> and they were what >> they wereic and and sometimes so I mean my only concern is if it is structured standardized based on evidence based on facts it's great you know lot of this my father is an ayurveetic doctor. I become an ayurveetic doctor. My son becomes a ayurveetic doctor. That to me is something I don't think is >> logical and good. See I mean I tell you prasad there is a >> if there is I I mean I if there is an education system and it has standards and >> aish college in Goa only they have one being one.
92:20 >> I tell you in this world there are many world in pharma world there are many worlds. There's a world of cardiologist there's a world of >> no for it is great [clears throat] for health wellness it is great because there is good in all this the herbs we eat all that but I think it should be treated like that it cannot be said that weather is better let us do this that kind of >> so everybody knows it even doctor knows it if a patient is coming to him >> and if he prescribe only product >> the patient will not come back to him >> because patient needs thought instant relief, faster relief.
92:56 >> So some element of ayurvea can be mixed into a traditional curriculum for wellness. >> Yeah. >> For wellness preventing and wellness is not a topic at all in today's just think somebody who just practicing >> he wants one money as well. The money will come through patients only. Why you I mean see u we all want to have money to run our life. Doctor it's very noble profession but he teacher is very noble profession yes >> but why not a teacher should be given a better salary >> and soon maybe anyways with AI all doctors will be a computer >> that's a point see if a chemist can substitute the product if chemist can say is that the system we want to build for our country it's happening with pilots also >> now they're saying pilots don't need to go to like actual plane you can go to a sim No, but you know their AI makes sense because you have >> um safety.
93:56 >> He will not agree with >> Tesla is safer than me driving. >> I tell you how many scientists will not come to this side because he I come from that side. I've seen the first of >> the science is good. We should I'm saying no no the logic is good. Sometimes without logic practical knowledge of a person the patients he has seen the people have seen and treated and cured. Sometimes you'll find in small villages there's a aruidic doctor he's using a very that particular area's medicines >> full respect to that I mean if he has knowledge wisdom we should use it >> but as a system does it scale does it you know >> right but if this is growing it's I'm seeing aish doctors >> so I would suggest that the opportunity here is wellness >> and like you said longevity to it >> so around wellness it can be tourism it can be supplementation can be the you know yoga workout all these things right >> biggest in our >> opportunity >> would be prevention side >> or immunity side [clears throat] >> okay but before we leave this topic we came to the conclusion that Aayush is growing at 17% by Aayush I mean doctors Ayurveda shilit live 52 massages longevity wellness sexual wellness >> yeah market supermarket best market where shily sells cells where it cells >> isn't ash for stress >> stress is for stress >> stress no are require it is being used as >> what what percentage of sexual wellness growing at >> tremendous >> you can imagine >> really >> maybe in this 17% 30% would be in [laughter] sexual >> wellness no you have a brand right so you have a viagra I mean this man force >> yeah man force that's a big seller.
95:48 >> Is it vibr? >> There's bold care scaled to a certain point and has slowed down. Why is that? >> No, they basically are in the process of selling the company. >> Right. >> Right. When you sell, what do you do? >> Spending is less. You're supposed to show profits. >> Right. >> That's the reason that >> I'm an investor in B. I'm in. >> So you must be knowing it. The ad was what worked for them. I think that Tanme did a spectacular job of shooting that ad with Ranir >> marketing is so much >> marketing >> but again I mean I tell you honestly I like your boldness you know you >> I tell you one more >> we can't do that we are >> I tell you more >> very inward looking that way >> see one more thing is there marketing does not mean that you pick certain USPS unique selling points or certain special points of your product and >> project it amplify it and give it to the people. It also requires right from formulation >> to packing to flavor to taste to doses and then you make it so good >> when you market it.
97:10 >> I say uh this is a great product. This is marketing and I acquire you as a customer, you buy it. >> But when you buy it and you use it, >> you say okay. On the second side, you say amazing. >> M >> then I'm not only I'm acquiring a consumer, I'm getting a loyal customer who will just market my product to other people as well. So it is actually in the hand apart from marketing what basically matters is what is your product you market a bad product maybe it will sell right but longer run it will fizzle out I'll ask you another question like [snorts] sexual wellness products like condoms and Viagra and all of that there is a societal stigma that people feel shy it's also some in some ways a Indian thing. I mean I if I have ever tried to buy a condom, it must have been a terrifying experience for me to go to a pharmaceutical store because we're just like that, you know, like if if you're buying sanitary pads when you're a kid for your mother or you're buying condoms.
98:29 Do you think there's an opportunity for a business which is online only sexual wellness all these products? >> Yes. >> Yeah. >> Yes. And if you just look at this right now, there is approximately 50 60% growth of condom sales online. On online is just on the fire, >> condom sales, pregnancy card sales, sales people want in just 10 minutes. But then for most people who live with their families even when the delivery happens isn't it a worry that my mother will open somebody else will open the box >> quick commerce no >> 10 minutes by the time your phone >> you you are present present at that particular time >> right true selling reich >> so actually you're right >> huge >> even uh these pharmaceutical products >> and the second >> link is selling them like crazy >> apart from this >> just one more ask one more question.
99:29 >> If I have some problems, sexual problems, >> will I go to a known doctor? >> Will I go to a chemist? >> Known >> I can talk to some unknown face online >> who can give me solution. >> I I can follow him >> because he does not know me. I don't know him, >> right? >> I just want a advice which is coming from a unknown personality. So there's a I mean uh secrecy.
100:00 >> Yeah. >> Because even when a patient goes to a doctor and doctor tells him something that this is your problem, >> he comes back >> uh with this kind of feelings that >> in front of his doctor I've lost my I'll say mangi or respect or whatever you call it. >> So whenever he goes with his family or wife >> Yeah. It feels a bit let down. >> Yeah, >> I was seeing the numbers of fertility businesses like people trying to conceive a baby even that is growing like mad.
100:33 >> It's going crazy. >> We had one company >> Bat BSV >> that company's specialist in this one >> fertility IVF >> IV. Yeah. >> And even like women who want to have children later in life that seed what is that called? Egg uh freezing eggs that's also growing like crazy. I have so many friends of mine who >> you're getting married later in life and priorities >> it's all career priorities >> there's a reason for that education urbanization women coming in jobs late marriages carrier first and I'll see kids later on >> and at that particular time I mean after 30 >> m >> that I mean uh f body is not that that much fertile >> with every passing year after 30 20% 30% it is less fertile.
101:27 >> Yeah, >> that's a problem. Another problem basically is what there are number of days >> in a month which is more fertile. >> So we were just talking so why don't people really go on those seven days. So some doctor said me >> how are you sure >> that on that particular moment >> they have something which >> so now she's most most fertile or this agon this spam and oa will just fuse together so now people are doing what they're taking a short honeymoon on in those seven days for 3 days >> and how do you figure this out through medication >> yeah there's a kit there we make those kits as well >> right so if somebody does you can't add sexual wellness with this though, right?
102:11 >> With with >> with which date what and all of that. Which date she's ovulating. You can add all of them in one business. >> Why not? >> And it should not be called something sexual. Then the stigma is lesser. >> Yeah. Yeah. Yeah. That that's important. You look at this how this this company is promoting their brands. How this any >> your company >> how they promote. >> Yeah. Yeah. But it is like that. I mean net net I think the way the world is going I might not have children but the world needs children because too many are not having any I guess.
102:45 >> Mhm. >> I don't know about India but the world needs more children. >> Yeah. >> India too actually when you look at the average age I think it's gone up from 24 to like almost 30. soon if we don't have kids I think that fertility ratio has dropped below 2.1 which is the replenishment ratio in most states outside of Bihar and UP or something people are not having two kids >> uh any state which which is more educated >> it is less >> I I mean uh more education is leading to less uh number of kids because they feel that to give education right kind of a schooling So much of money is required. You go in West Bengal eastern side one kid.
103:30 >> Yeah. >> You go to this Kerala. [clears throat] >> Yeah. Yeah. >> Can we do another digression? I want to take a science lesson on what is API, what is small molecule, what is big molecule. >> You'll have to tell me what all is there. >> Sure. Uh start with API, active pharmaceutical ingredient. >> Okay. >> That's an organic compound mostly but sometimes inorganics can also be there. which is actually the part of the medicine that is active in your body.
103:58 That's why it's called active pharmaceutical ingredient. >> When when people say I don't I have zero knowledge idiot like abs. >> When people say API industry is controlled by China, India doesn't have it what do they mean? >> I don't agree with them. I think the Chinese are much more low cost than India >> right >> uh due to variety of reasons >> right >> but on the front end they're not that good. But can we make without China?
104:25 >> Today we could do it, >> right? >> We have all the capabilities to do it. But the economics dictate that I buy and I don't make it. >> This is what I was saying. >> The economics it's easier for me to buy an intermediate. >> But if tomorrow China stops supplying, >> we can make it. >> Yeah. >> Most technologies are exist in India >> at scale. >> We used to make them before the Chinese were there. M so I don't see the technology as a limitation >> China brought the prices down >> because we could not protect I mean for example look at this intermedi intermediates right China does not give for example like take the example of antibiotics only lot of antibiotics are there >> in the absence of Chinese supply we can come into a crisis >> India will make it they're already making it now pencil even >> that level >> yeah So we were making these pencilins before China was making them. So I don't think it's a question of capability. It's just a question of our focus.
105:26 >> The question basically is what the question should be asked is why did we stop making >> because it's cheaper to buy. >> Correct. >> Yeah. So and I would not criticize that. >> Right. >> There is no need of national security on this. >> It's availability you buy it. If they can't if the availability is not there you make it. >> Oh now this is a national security. >> Pardon me. >> Now it is a national security. I don't agree with that. I I mean that's a point of view always. But I feel we are pursuing the value chain. We are capturing more value from these products. We don't see the Chinese competitors in the finished products anywhere including emerging markets where they should be strong.
106:08 >> We are selling in China. It's a global world. Why are we saying national security? >> No more global world now. In time, >> I'm telling you this, in co time, we had more reliable supplies from China than from Indian companies. So what is this thing about national security API controlling by them? This is all a narrative I don't believe in. >> Do you believe it in batteries and energy and all of that? >> Maybe because there's a supply there.
106:32 There is you know source of raw materials which we may not have right >> and that is strategic and they've threatened to control it. But in API there's no control. There's no threatening there. It's all available. commerce system. >> If China stops tomorrow, we can >> Why would China stop tomorrow? Let me ask you that question. >> Like China threatened us on dead earth. Same logic. >> Yeah, but there's still supply. >> But for a while, it was negotiation.
106:55 >> Yeah. I mean, that's common in global politics. >> If you bully and I you want to be the only bully in town, they're going to you be bullied back. >> So that's what happened to the US. >> It's like saying food security like should we import all of our fertilizers or should we have capacity? But we are not importing all the pharmaceuticals that we need from China. That is not a narrative. >> APIs. No >> API. We make a lot of APIs.
107:17 >> India is a big exporter of APIs. >> In fact, the competition is severe among Indian companies. It's not the Chinese which are competing with us. >> So where does >> Chinese are in a big different league actually Chinese want to basically have huge profits. >> So why should they spend their lot of money? >> They will sell biologics. But yes, it's a >> even biologics will tell you this issue. Even biologics will tell you this. They need us to sell the product.
107:45 >> They need Indian companies or western companies, more western companies than Indian company to sell the product. >> But tell me this as a very very lay man like somebody who knows nothing. When you say organic compound, I'm still confused. >> Okay. It's like um you take simple molecules like starting materials which are called uh basic organic chemicals. >> Okay. Then you react them to get a more complex compound. That's an intermediate. Then you combine some intermediates to get the final product.
108:14 >> That is the API. >> The final product is the API. >> API. Yeah. And the API has to be at a very high pure purity level. It should have impurities below threshold. >> I know eating paracetamol. Where does API come before? >> Okay. Paracetimol. >> It goes into my mouth. >> Paracetamol is the API. >> Okay. The tablet you're using it contains 500 mg of uh paracetamol and a few other binders and other things which make it deliver the paracetamol in your body at the right place.
108:41 >> Okay. >> So that's the formulation. Formulation is what we talked about so far. The pharmaceutical indust >> for example when you take a paracetamol tablet the weight is not 500 mig >> the weight is more than that. >> Yeah. Inactives. >> Inactive. >> Active is the paristimol. Paristimol actually chemically is paraminophenol reacting with acetic and hydride. Paracetamol is a short form of it. >> Moxy I'll give you the synthesis of parasol. I don't know if it's going to be accurate. You start with something like nitroenzene or something reduce it to make amino and then you acetilate it that becomes paracetamol.
109:23 >> Right? >> So the three four reactions involved. Finally you purify it and formulate it. So the powder that we sell as a chemical is paracetamol >> and that's API. >> That is API. >> Okay. >> Yeah. So like that you have ibuprofen, you have >> those are all APIs. >> APIs the active ingredients. >> Now biologic product is much bigger. These are >> API biological. >> Yeah. >> In terms of ingredients, >> these are synthetic >> API synthetic. These >> synthesis call it synthesis >> organic synthesis.
109:55 Um these are smaller molecules biologics >> no the APIs that you're talking about they are smaller molecules they call small molecules bulk drugs APIs all these various terms are used >> raw materials >> so basically that is a molecular weight will be at most thousand 2,000 is the highest limit around thousand is the >> thing after a certain size they become large >> and they synthesized by living cells. M >> so what you do is you um develop specialized cells >> which make the ingredient that you want biological systems it's not synthesis is like Lego works you're attaching molecules >> API is a Lego block >> yeah whatever >> you block two three four smaller Lego things you get a bigger one >> but it size is four >> yeah size four blocks just for example >> yeah four 5 10,000 2,000 >> yeah whatever but Here it's a living body, living cell, living cell >> in biologics, >> biologics which you inject a clone >> to produce a certain product and it could be as simple there are different kind of cells to make the science more complicated.
111:11 >> This is interesting when you say inject a clone what do you mean? [music] >> [music] [music] [music] >> You you take a sample of DNA >> and you modify it. It's called recominant DNA.
112:01 >> Okay. >> To tell your cells >> to produce this, >> right? >> Which is your I'm done. I don't >> try try some. >> That's a lot of food. I can't have this. >> No, just try a little bit. Um >> and then the uh cell >> you grow the cell you multiply the cells you feed it >> uh >> glucose or whatever to grow multiply the cells >> cell is like a real living thing.
112:27 >> Yeah it's a living unit. >> Where does that come from? >> There are various kinds of cell the mamalian cells which are complicated. M >> you can [clears throat] use yeast cells >> which is a high yield low cost and then you used what are other kinds of cells insect cells plant cells all of this produce something in the we are actually producing many things as we live our lives >> so in biologics you're taking a cell and putting a large number of API together which is more than 2,000 >> no no no sorry you have not reached the end this is different you this is over remove that from your mind okay now you're making these are chemical drugs Good sir.
113:05 >> These are biologic drugs. >> Okay. >> Biologic drugs are larger in molecular weight. >> Okay. >> And um they are produced through a variety of means. I'm not a biologist. So if I'm saying something inaccurate, >> forgive me for that. But in in a very broad terms, these are drugs produced by living cells. >> Okay? >> And cells can be many types of cells. Okay? Insect cells, mamalian cells, yeast cells. >> Okay? uh they you you modify the cell by putting in a clone of uh DNA into it >> and it multiplies.
113:37 >> Okay? >> So you grow some cells, you grow them in a larger vessel, then you take them to production scale. >> Okay? >> You have what they call the seed cells, right? >> You clone them and then you multiply them to a certain size and then put it in large fermenttor. There it's produced. >> The cells produce this. Then you have to kill the cells, >> right? After they grow for a while and you get the right uh product in the produced in the cell, you destroy the cells. You actually break the cells and extract out the product that you want >> right >> from the cells. This is broadly I mean it's not very scientifically accurate what I'm saying but this is the broad process.
114:14 >> What are some examples of biologics? So he talked about ampecilin the penicellin there is a biologic drug actually though it is not called used for >> it's an antibiotic broadsp spectrum antibiotic >> the first antibbody no >> uh so antibiotics come under biologics >> no not every >> syn antibiotics are synthetic as well >> and they're actually semiynthetic >> semiynthetic >> you take a biologic you combine it with a chemical you get a semiynthetic >> so that's a complicated thing don't just take take that Your GLP ones are peptides.
114:48 >> They're larger molecules. >> Now they're not biologics. >> They can be done as biologic. They can also be done as synthetic. But synthetic is very cumbersome. You have to do a long synthesis, >> right? >> Um and that's a class of compounds called peptides which are made out of amino acids. >> You can also tell I mean where these biological biologics are used actually >> autoimmune diseases. >> Many diseases use biologics from simple diseases to complex diseases. He's talking about the targeted biologics.
115:14 There are a class of compounds called monoconal antibodies. >> Okay, >> monoconal antibodies. These are like they call them the silver bullets, >> right? >> They go right to the place where your body needs them, >> right? >> And latch on to the target, >> right? >> So, they're more precise. They're more accurate. >> They're more effective for many diseases, especially cancer, immune therap immunology. >> They're all biologics. >> They're all biologics. >> Where do vaccines and all come?
115:40 >> Vaccine is a biologic. vaccine. >> It's made from a virus. You're actually taking a virus, immobilizing it so that it doesn't cause you damage. You're putting it into your body. >> Your body recognizes the virus, >> develops antibodies, >> right? >> So, >> now tell me what are stem cells? >> Peptides. I I recently got a lot of stem cells. >> Stem cells >> and the doctor told me it's from some umblical cord or something.
116:04 >> Yeah. Yeah. >> In another country where it's legal >> are a special kind of cells. They can take they can become any part of your body. I mean they can >> they can become muscle they can become bone they become skin they can become your organs. So they're like magic >> and when they say say they're from donor embryo umbilical cord what do they mean? >> It means stem cells are not everywhere. We won't have stem cells.
116:30 >> Stem cells are when newly born children >> they have them in the umbilical cord. The mother produces stem cells by which this body of nature is produced. Right? >> So the stem cells are there in the cord that is attached >> to the mother and between the mother and the child. >> So that is stem cell rich. So they harvest the stem cells >> and you can get unlimited stem cells from one umblical cord. >> No no you can you can multiply the stem cells once you isolate them. You can grow them.
117:03 The origin is the umbilical cord. From there you can multiply it. >> So my question is one umbilical cord can have enough stem cells because of multiplication for thousands of people. >> There must be some limit to that because I think they get tired and they don't reproduce that. They they don't divide so much >> and peptides come under stem cells. >> No, they are not stem peptides are not cells at all. >> Are stem cells good?
117:28 >> Stem cells are cells. They are not good or bad. >> No. Is there science to say that they're good for us? >> They they are being used for therapies now. >> Um >> should I be taking them? >> They are not FDA approved if you're asking me that question. >> No, I'm not asking that question. >> I'm asking should I take them or not? >> Depends on what your problem is. >> No problem. >> You shouldn't take them.
117:48 >> No. >> No. >> Really? >> Yeah. >> Why? >> They're all you know lack of evidence. They just you know do something largely originating in Korea, China. >> Maximum. >> It's business. It's not >> in Dubai also. >> Yeah. But if you do a research on the websites of the FDA, >> you'll get sound advice not to do it. >> So some people if you have a knee problem, >> cartilage is damaged. The stem cells can grow the cartilage is what they're saying. But again, it's still not >> medically proven.
118:20 >> For cartilage because I play a lot. >> Yeah. You can't put all this in. So it can reach in my knees and elbows. I get salmon sperm DNA. Is that good? getting me into controversial areas. >> But I take all this. I'm asking actually for myself. >> You're advising I'm actually taking them. >> Has it helped you? >> Has it helped you? >> I don't know. >> These are all >> I get tennis elbow, but >> I don't know if it helped or not. And I get this sound in my right knee which is like tuck tuck tuck tuck because I play a lot.
118:53 >> I play 2 hours a day. So >> every day. >> Yeah. >> How do you play? Well, you should when you go to the US, you know, when you go to the US, >> go to Mayo Clinic, >> they have a wellness program. >> Yeah. >> And they'll screen you for everything. >> Yeah. >> And they'll give you sound medical advice. >> Yeah. >> But is there like if I >> So there's a lot of hype around peptides around >> Spalman. I'm heard hearing it for the first time. [laughter] >> I've seen salmon sperm in >> getting it injected in their face and all.
119:23 >> I wouldn't do it. Mhm. >> Dubai is a place, >> huh? >> Dubai is a place. >> They're getting injected to their face saying collagen will be boosted. >> Collagen maybe. Yeah. >> These are all non-medical issues. I >> peptides. >> So peptides are a class of compounds. >> Your body has peptides. >> Okay. >> Peptides are smaller than proteins. >> They're made of amino acids. Proteins are also made out of amino acids. But these are smaller in chain.
119:51 >> 30 40 amino acids. 50 60 70 more. Proteins will have hundreds of them, thousands of them maybe. So it's a class of compounds which are becoming large part of the therapeutical basket. >> Right? >> So semlutide is a peptide. Discipide which is monaro is also a peptide. >> This is a big one. Semaglutide. What is the story like? What has it's like the whole world has changed. I have heard 10 friends of mine who want to start business in JLP1.
120:21 >> What is it? So they'll start the business in GLP1. >> How what they want to do? They want to sell this product. >> Yeah. >> Again I tell you one >> it's a prescription product. They want to sell it. >> See forget >> they'll build like marketing around it and create a brand. >> Forget the business for the prescription. >> I mean how many people are using it versus how many people are abusing it. >> So whenever a product becomes super hate >> right it is being abused.
120:47 >> Correct. M >> I want if patient forces a doctor >> he say >> then it really happens but just imagine if >> I think you asked a very question where did this come from >> this is a good question to ask this is a product which your body produces actually >> GLP not GLP1 G not glucagon like peptide >> but a peptide called glucagon is produced in your gut it creates sassity in M >> and um the only thing is it is not stable. If I had to just apply if I just take that and inject into you it is not a stable molecule. So the Nova Nordisk after doing a lot of research wanted to extend the halflife of this product >> and they made some changes to that peptide >> which became semoglyide >> and your body yeah your body has multiple hormones >> which uh trigger your brain activity to say stop eating or you know your sati is very high you can't eat or if it is deficient you eat and then become overweight. So if you control the level of these chemicals, your um uh your craving for food comes down, >> right?
122:05 >> And then you don't feel >> in the head or in the gut. >> It's it's it's head and gut. They say there's a connection. I don't understand that. >> A lot of people say that. >> Yeah. So but it is largely gut. >> Mhm. >> I mean, but they're circulating in your body in the in the blood and all that. So there is a very good chance they're going there also. And when you say noon not has figured out how to increase the half-life.
122:28 >> Yeah. >> It still disintegrates but longer. >> Yeah. Yeah. >> So whatever the issue was in the beginning is still there but it comes after a while. >> No. No. Not that way. Not that way. Every every chemical has to go. It can't stay forever in your body. So the halfless >> even if your body creates >> even if your body creates your body is circulating lot of things metabolizing them all of that. So your body produces chemicals on demand, antibodies on demand, >> all of this.
122:59 >> So it's a continuous system, very complicated, complex system. So when the GLP ones, they figured out that this hormone has a role in hunger, >> triggering hunger and all that. So but they couldn't find a stable formulation or a stable keep the product long enough in your system to make an impact that they figured out uh through the semaglutide. That's how seamag came. Around the same time, Lily also worked on this, developed their Munjaro >> and it took them I think.
123:28 >> Are you for it against it? Like is it >> I would I'm for it because >> it helps a lot. >> Yeah. Not for maybe you and me, >> but if you're clinically obese, >> you have hypertension, you have cardiovascular risk, you have metabolic syndrome, you have diabetes, >> and [clears throat] in some cases, they're now saying even uh Parkinson's. >> So if you lower your weight, >> there's so much risk which comes down. Of course, it is not easy to >> especially metabolic disorders in diabetes, diabetes, they can prescribe.
124:01 I think it's a great product. >> Yeah. >> But you know it's not for making a model who's slim to be slimmer but >> but where the use is happening >> newly uh brides or uh those who basically are about to get married >> I mean anybody who wants to lose weight lose weight without doing anything there >> but the problem is >> because you also lose muscle >> muscle. Yeah that's a problem. It's not just fat that you lose.
124:31 >> You lose [clears throat] muscle. >> And once you lose muscle, they'll not come back. No, >> it'll come back. But you have to do a lot. You have to increase your protein intake. You have to work out all this. So along with prescription, there's a list of things that the doctor should be telling you. >> So, so we we have launched this semiglutide with this philosophy. Our philosophy is totally different. Number one, >> talk about the side effects contraindication just to get >> all of us talk about it. It's not like we don't talk about it.
124:58 >> We are ethically bound to talk about >> point is what? >> We start with this not don't we don't end with this number one. Number second >> just remember at the time of gold rush who made the maximum money >> those who run for >> gold or who basically sell the ancillaries right correct >> so what our philosophy is along with this our focus would be on supplements I mean this would be front end but actually we will be selling the complete lifestyle >> protein supplements vitamins other requirements the complete I mean chain the ecosystem [clears throat] we have created for this particular division that's our concept and again I tell you honestly in pharma industry nobody talk side effects >> one of my friend once told me >> I debag a and you are painting in a very broad way industry I think we all are bound by the >> you write down >> ethics of running a prescription driven business >> don't take it personally but you write >> not personally I mean you the industry that's why protecting that that >> have you ever seen a sales trap because I've spent my life right talking first about the side effects versus effects you'll not find one you'll say yes these last >> but you have to start with the disease you're trying to treat it's not that you >> if I know if I know 50 brands are there 50 companies are promoting I'll not promote that I'll say no take precautions this is not a shortcut I just want to come in the limelight through this.
126:35 >> Yeah. So, >> and then promote me other >> in a in a way it is called ethical selling. >> There's no ethical >> pharmaceutical selling is not supposed to cross some boundaries >> and we should not >> and I think largely the bigger companies top 10 companies don't cross that line. There are companies who will sell you anything >> under a promise but I don't believe that the top 10 companies do unethical selling >> in India. I don't see it so much in the US. If I'm watching a TV news channel, half the ads are pharmaceutical drugs.
127:09 >> Yeah. >> Their direct to consumer is allowed. Here it's not allowed. >> So it has consult your doctor. >> No, they say you'll have vomiting, nausea, headache, this that they say all of that. But they're still selling. >> But you'll find that how boldly they write, >> what letters they use, >> how much they how much time they spend on explaining the side effects. >> You'll find that properly. >> Yeah. They say 20 diseases. >> Yeah.
127:33 >> But nobody pays attention. They still buy. >> That's fine. >> Yeah. >> That's okay. >> But I'm telling you, >> but you know in the US you can't buy a drug just like that. >> You need a prescription. >> Here it's easier to buy. Uh you can go in and buy a Noxilin from your corner pharmacy. >> Right. >> In the US try to get a medicine without pharmacy registered prescription with all the details. >> So you both make JP1.
127:57 >> Yeah. I just want to make an important point here. I I agree you have a point of view about marketing and ethical but our industry is a ethical industry by and large 100% of the top 10 companies don't do anything wrong is my view uh I have not seen this I mean I I also go and talk to doctors I go and see them there are small companies this is a very large industry hundreds and thousands of companies are there who you know may be doing many things wrong but >> you have 10,000 reps how do you know what each person is saying >> monitor them And if a doctor complains and we do get complaints, it's not that everybody is ethical. We get we get written complaints saying your do your med said this, he shouldn't have said. I said yes, let's call it try. If you know, we won't keep quiet.
128:44 >> Okay. More importantly, what is the business opportunity here? >> Yeah, let me You started with peptides and then went off into GLP ones. Peptides are many things, not just GLP ones. There are many peptides. And now since you're into very big into fitness, >> there's a whole wave of peptides >> being marketed to young >> for sleep. >> Yeah. For sleep, for >> sleep protocol, GHK, CO, copper peptide. Yeah. I'm taking one or two. Yes.
129:10 >> Yeah. >> Um, [laughter] consult your doctor. >> I'll try everything. >> Yeah. Yeah. So, peptides are a class of compounds which are becoming very important even in the pipeline. M >> the pipeline has and this is an important shift in the industry. >> Pipeline used to be largely small molecules. >> It's now shifting to large molecules in biologics and peptides and also another class of compounds called olonucleotides. just say peptides subass of that >> this industry India is not great at in biologics >> in this industry >> biologics or peptides >> all of this >> in biologics in small molecules we are the masters we can compete with the China of the world any >> the generics fall largely under this >> yeah generics are across the board they called different things here but I'll come back to that generics is a formulated version of the ingredients the actual substance that works >> once something can be made by everybody.
130:08 It's a generic, >> right? >> So, a API we used to be the king of this this thing, >> right? >> The the value of the pipeline used to be 80 90% this the rest used to be vaccines and small small biologic drugs >> like enzymes and things like that. >> Now, because of the improved efficacy, >> the precision of how they work, >> this has picked up a lot. biologic drugs >> and this is where India needs to pick up.
130:39 >> Indian abilities and scientific and manufacturing abilities in biologics are lagging. >> China is way ahead of us in biologic drugs. >> I wouldn't say that in chemistry but I'll say that in biologics. >> Which is Kiran's company? >> Kiran's company is very much in biologics >> and [clears throat] for all her success she's still 2 billion or three billion. I don't know what her revenue is >> but the companies that are competing with her in China are massive now >> in in the number of products they're developing and all that. Kiran's company is the leader >> insulin thing insulin something she makes that's >> insulin is also a biologic drug yeah originally insulin was extracted from porca and uh pancreas I think >> but now it is synthes it's ferment developed through living cells >> so this part is something the companies have to invest in >> this is also the part where there's disruptive >> science developing technologies developing >> and could be opportunities but not for a general 25 year old but somebody who's deeper in technology who has a background >> say maybe Indian of science >> or I I those are the guys who can think of this >> if 10 chemistry biology people get together can they start a company in something here >> they need a lot of capital >> which is not available in India >> it's not easily available I would say but it's available they can do innovations >> and connect the dots to a larger company and in Bangalore you find CC camp and all some of those are doing some interesting work >> you can also generate novel biologics at a relatively lower >> intensity of cost than small molecules it's easier to develop >> can I ask you a question during co >> somebody discovered co shield and some other some other vaccine >> I think bharat biologics had one somebody in the UK had one What was that?
132:39 >> That was really once they knew the sequence of the virus, >> they rapidly developed the the vaccine. >> So once you know the cause of the disease, >> if you isolate the virus and you can understand its RNA sequence, >> it's like computer code. M >> you can develop a a virus without the harmful effects of the um regular virus >> and then develop a vaccine very rapidly.
133:09 >> Testing is what takes time and during co I think governments understood and accelerated the approvals and pushed the >> envelope in terms of not requiring very high number of trials over large numbers of period. They did some emergency policym and developed a vaccine very fast. >> In US politics >> now you hear a lot of >> antivaxers. H Fiser did this they knew this people getting heart attack stroke young people. My brother had a stroke.
133:39 He's very healthy 45 year old. >> Do you think there's any truth to that? I'm not scientifically qualified to say that but there is a lot of noise about >> isolated uh strokes, heart attacks >> coming from clots >> which travel to the brain based on the vaccines. >> But overall if you see without the vaccines we wouldn't have gotten out of the co pandemic. >> You think? >> Yeah, I'm 100% sure. >> But once you have co don't you develop some immunity?
134:12 >> It's like getting a vaccine. But the but the vaccine the the virus is mutating >> and it gives you some protection but you know even people who got vaccinated got some uh second this thing and all it's a whole different science which I don't fully understand but vaccines have played a big role in eliminating many diseases like polio measles >> many infectious diseases >> today you know I think the world is a much better place because of vaccines.
134:45 >> No, people today live till they 70. 100 years ago they lived till they were 30. >> Something has changed. >> Vaccines could be a part of the >> vaccines uh nutrition, >> maternal health, >> lot of things have increased longevity. >> But any business opportunity? I keep going back to the 25 year old. What is the opportunity here? >> See if can I start a JLP1 distribution business? Start a brand. I'll buy from you. I'll buy from you. I'll do marketing.
135:15 >> You know what you could do is have everyday counseling for a guy who's on a GLP1. JLP1 is everyday problem if you're on the GLP1. >> Yeah. >> Yeah. It's it causes bloating. It causes uh >> so like a app that counsels people who are taking JLP1 >> app or even you know humanto human counseling. >> You don't need to be a doctor to counsel. >> No, you can be a nutritionist. You can be a fitness. What if I find two fat people who became thin? I have a friend in mind.
135:43 >> Yeah. >> And they start a brand of GLP1. I'm buying the >> product from you guys. >> That is gone. That that that is already mainstream now. >> Yeah. >> Yeah. >> But I do great ad basically I mean see you give example that this GLP has done this >> but 20 brands are there of GP >> they already >> 20 good companies are giving goods. What is the company's name of yours? your friends nothing is there that's the point on the contrary I mean this is the time when this there's I mean wave of GLP which is going on people want to cut down their weight >> and they know it very well when we see that >> the muscle loss would be there >> right other factors are there >> so there that site can be promoted and there some kind of a business can be developed what we basically Imagine that going forward the sales of protein products different kind of protein supplements protein supplements vitamins minerals other enzymes coin all sort of things >> they will further increase because now people are cutting down the weight knowing at least in the back of their mind that these are the problems going to happen so I'm supposed to go for some exercises should I eat this >> so because I'm doing this so I should do that >> so some kind of way I'll say pulifact could be there right >> let me ask another question is there no difference between vgovi mjaro >> munjaro is different >> how is it different >> it's a different molecule >> can't I take your GLP1 add something do something >> don't please [laughter] >> so you you have really I mean taken this FMCJ too seriously Yeah, [laughter] >> I I I think you have given him more confidence than he [laughter] should have.
137:43 >> Yeah, >> that's not a good idea. [clears throat] >> But I can do a counseling company along with all the other supplementation required into one. >> No, since you're saying this, I'm just looking at what you do. >> Yeah. >> You got a fantastic gym. >> Yeah. >> You got a chef who's measuring your calories and doing it >> and then you eating clean. Yeah. >> And all this >> this is something we don't get. All of us get an opportunity to practice.
138:08 >> You get >> others don't >> I maybe choose not to do it or something [laughter] but whatever. >> Yeah. But you know there are nutrition companies, there are companies which will tell you about fitness and see here. Obviously the why counseling is would be very very important because everybody knows it that there would come a time when he will stop taking these injections and if after that he will not take certain precautions whether eating right products, proteins, supplements, vitamins, this this and some kind of exercises. M >> he will gain back faster and this time whatever he'll gain will not be will not be muscle will be fat only know >> right >> so have you seen certain celebrities look at their faces >> what has happened >> that's the problem >> so point is what if you [clears throat] take these things along with certain right kind of counseling and precautions and certain supplements this is a business >> and add add some kind of flavor in those Don't sell run-of-the-mill kind of brands in terms of anything and everything. Just go I mean somebody should go for a deep research and see what are the flaws in the present product >> whether supplements whether white beans and >> this I mean >> the only the point is not only the effects point basically is also packaging plays a role look and feel plays a role taste plays a role. M >> I mean sometimes we when we have made a research we found that lot of uh ladies during pregnancy time can you take a calcium tablet because it's too big in size so can you cut down the size of the product >> can you add some kind of flavor the coating because they have a nothetic feeling always >> right >> so these are small things but they are very important things >> but you know to sell these products you need a sales force you need all this promotion so for a year >> it can't be done through advertising thing like say for example I built a protein brand >> it has worked >> can't I build a GLP1 brand like that >> no you can't a prescription >> yeah but then you can't sell it >> oh you can't do an ad >> can't do an ad you can't talk to a patient >> medicine any no medicine >> we cannot talk to a patient >> no medicine can be promoted through through advertisement >> even online you can't no >> what if I see an American ad in India on YouTube >> you can see that that will not run on TV on broadcast >> YouTube possible. How can you sell American product here in India?
140:45 >> No. No. He's saying if Lily has a ad on Munjaro, you can see it on YouTube here. >> That's all right. >> You can't. >> Isn't Lily sponsoring something in the IPL? >> Yeah. Yeah. >> Just some ad coming. >> They're not seeing it's like literally >> Yeah. It's like how whiskey companies market, you know, soda. >> True. >> Music. >> So, I'll start a GLP1 company. I'll call it uh NKGLP. I'll hire like a fat person who became thin to be the hero of it and then after IPL match I'll say NKGP ad we make protein powder. Is that a possibility?
141:20 I'm just finding every edge case for a 25 year old. I say big no >> the case against what you said is >> it's illegal >> right >> in whiskey it is probably gray and there >> the government against it is there any part of the value chain that is finding its way to America even now after the patent is not there >> no no America the patents are still on >> no but in India when you make it do you have to pay them anything >> no we do it after patent expiry >> then government doesn't like it because >> government doesn't like it because it's a pharmaceutical product it has serious side effects >> and you can't promote it to people who are >> gullible. [clears throat] It's a it's a when muscle loss, problems in the bones, other so many issues are there. People are not basically looking for those side effects.
142:05 >> I I I just tell you why I find this difficult to find an opportunity for a 25 year old is this is a deep science business, >> right? >> You have to have technical skills, all of that. >> Marketing is important, but the product is much more important, >> right? And you need to have the right products and the marketing overlay. >> But the 25year-old is not making the product. He's buying it from you. He's building a brand on top of it.
142:29 >> You know, if if there was any arbitrage in that, I would have done it myself. >> There's many cases where there are arbitrageages and people do it. >> He will not be I mean see I mean this product please understand that this product has to be prescribed only even if a patient is buying it. >> So right I'll tell you a prescription of a doctor >> came in [clears throat] the US. They have something called compounding doctors, >> compounding phys compounding pharmacies.
142:55 Sorry. They actually buy the JLP powder from China and they mix it into injectment, load it and ship it to customers all for products which are under patent but are under supplied. >> So both Lily and Nova had supply issues initially as the demand rose much higher than what they projected. >> Right. >> And these guys made billions of dollars. >> Yeah. >> Young guys. All they have to do is contract manufacturing of some product, buy the ingredients, putting it together. As a pharmaceutical company, we don't want to do it because we are scared of them suing us. These guys made huge money.
143:31 >> I know a guy who was sold more than a billion dollars worth of product at 80 90% gross margin. >> But you can't do that in India. >> No, you can't do it in India. There's a grand there's a rule in the US that if there is a shortage, you can the pharmacist can compound it. >> Another question. If you guys are operating at 20 to 25% ebita which is quite high >> why doesn't the like you were talking about my chain why doesn't the yin the guy putting in the money to research >> take over this profit center himself >> so in many countries they do so I'll tell you the yin and yang in what context I told you that >> the the innovator is making is spending billions of dollars developing a product launching it globally and making a lot of money >> right >> through a monopoly rights patent rights give him monopoly rights for extended periods of time usually it's less than 10 years >> after accounting for all the time it takes and develop 7 years 8 years >> and the profits are massive they're selling at you know huge prices >> and that is the innovator's business so it keeps on innovating and then doing it >> as a generic company our approach is to get the patent life as short as possible so we'll find a loophole to get in early, challenge the patents and say they're not valid patents.
144:51 >> So we fight that. >> So we try to shorten their useful life of their monopoly thing. They fight to extend it by suing us. There's a constant legal battle. >> This is the yin and yang. >> Mhm. >> The people uh doing the generic cannot sustain without an innovator there because if there's no innovator, there's no generic. M >> and if we don't bring their patents down, they'll have monopolies forever and they won't innovate fast enough.
145:17 >> Right. >> So in that sense the generic industry and the innovator industry or the yin and yang of innovation >> why why does why do Indianies pharmaceutical companies >> spend only 3 to 5% of budget on R&D but the western ones spend 20. >> I think uh the nature of R&D we do is different. We do process development. We develop processes for products which are known and that doesn't require huge amount of money. But some of us do research. We do spend our our numbers are double digit >> right >> uh in R&D. The bigger companies are spending. Sun spends, Zida spends.
145:56 >> I think all of these are double digit >> more or less. >> The Indian companies alone don't have to do it because they're focused only on India. They're doing branded generics business. For our India business, we only develop products at a much lower cost 2 3% 5%. >> If you're basically [clears throat] mean spending money on R&D, >> you're supposed to have global presence then only it will make kind of a sense >> only from India not possible.
146:22 >> Is that the plan in the future like as a brand selling globally? >> See all of us >> we want to increase our margins. When you're sitting on the generic side, the innovation side looks so sexy. The margins are so good. The monopoly, right, it's swimming in money. A company like Fiser is what 6070 billion in revenue. Merc is even bigger. >> That's bigger than the Indian industry. >> It is bigger than industry. >> So if you want to go to that scale, you have to be an innovator.
146:52 >> But innovation and generics, they are not a continuum. People like to say we're moving up the value chain, we're going to innovation. It's a very different business. So business just me let me complete this kind of talk then you can come in. So generics is something that you know you develop processes you file you get it's all very predictable >> discovery research and finding a novel therapeutic is a long arduous process very high failure. So you're you're moving in from a business which has a large number of small tiny bets to a business which have very small number small number of very large bets >> the risk profile very different >> right >> uh so to move there from here is a big challenge and that's the challenge that's something that we're all facing >> requires much much bigger capital and we can't leave this business because this is our bread and butter and we need to keep funding that and then also create a new business with it's very demand funding in terms of science and investment.
147:51 >> This might be a stupid question but when say whoever created GLP1 created it >> if you got the product you can't reverse engineer it. Yeah, that's what we do. That's what we did, >> right? >> That's why we launched. >> And how? >> That's the generic. >> That takes a long time. >> No, it takes 2 3 years we can do it. Maybe GLP1 was a little more complicated product. So maybe four years. >> Otherwise, I mean the day it got I mean off patented.
148:15 >> Yeah. >> Uh after one week it was launched. >> Yeah. >> When you say off patent does it mean they disclose what the formulation is? >> No. No. We don't need that. Patents have all the details. Right. >> Patent expired expiry date in India was 26. >> So in the patent only the formulation will be there. >> Yeah. But we don't even need that. We can reverse engineer from the product itself. >> In in this case the Chinese are much better at biological processes and the GLP1 they make the semaglutide they make is from a biologic root.
148:49 >> So they're able to scale it much much better than Indians. Indian companies are largely in synthesis which is an inefficient way of making stemlotide. >> What else? Meanwhile, can you guys think of anything else for the 25 year old? There are one in 28 unicorns in India today. There is one in pharma drug innovation which is called malle bio. >> Mole bio. >> Yeah. H >> huh.
149:19 >> Testing kit. the diagnostic diagnostic >> that's not even >> it's not in the same >> yeah but you know you don't you it is innovative what they did >> the the diagnostics they developed were >> uh much much better and easier to you know it's tailored for the Indian market >> I mean if you just look at this uh you're talking about the R&D side in India >> why companies are spending less because we are now coming to the cusp of that place where companies have become a serious.
149:51 >> Why so? Because slowly and gradually what basically is happening government side from government side regulatory is becoming a bit stringent >> right more regulatory will become stringent. uh so naturally one day would come when every company man factory would be manufacturing a quality product >> right then the kind of advantage a branded company has [clears throat] like I said top 50 companies have more than 75% market share >> we lose that gleam >> right >> because why some patient goes to a branded company a known company because there is a trust M >> that if I buy I'm sure this is a right kind of a product on the other side because we keep hearing a lot of cases are there I mean that problem happened be that this problem happened and sometimes problem is not because of the drug which is there in the syrup or tablet >> it is in the exipient which was used >> some kind of reaction happened some problem came >> so those kind of an expertise are not there with those factories >> right >> so that fear is now there at least if you ask me in our head that maybe what what would happen after 5 10 years time >> so why not to now invest and come to a some kind of a level where we can rely on our own R&D so this is a big see company like us we spend 2.75% on R&D >> and what we've decided now every year we're supposed to increase it by 5.5% >> right >> and make it to highest level possible >> and then how smartly you use Right.
151:32 >> What kind of a talent you bring? >> But if you bring a right talent, they bring more talent. >> What is the CDMO industry? Is there opportunity there? >> Yeah, CDMO is doing well. The multiples are like hospital multiples now, >> right? What does it do? Explain. They do they work for large uh innovative companies to either do uh FTE based research full-time equivalent based research developing molecules discovering libraries of compounds and all that medical chemistry or even biologics. Uh that is one part then that is the CD part. M >> manufacturing is actually producing the product >> right >> since these companies have very good margins and for them security of supply is much more important than cost at that point. If you have a strong manufacturing infrastructure quality systems they will outsource the manufacturing to India. On top of this the uncertainty with China >> uh not just the tariff but also the there is what was that act called um the biosecure act.
152:42 uh for you know for their country's supply chain security >> they passed a biosecure act which >> encourage companies to move out of China >> right >> so there's a whole thing called China plus one strategy >> that's an opportunity for Indian companies Indian companies all the CDMOs are growing very well your own city has a nice uh one called Anthem Biotech >> is again a startup >> and these are small companies >> Anthem is big now >> yeah but you but someone small small can No, they were small ones.
153:13 >> They started with some small amount of capital rented premise. >> Today they're I don't know the market cap is what Tantham maybe 20,000 crores something like that. So this is a good success >> but someone small can try it. >> They can try. I mean these guys were scientists who working in Kan's labs >> right? >> They came out and started somewhere and built a sizable business. >> Not 25 years old. need to have some kind of a scientific experience.
153:42 >> You start when you're 25, you can work your way through for the next 10 years. >> Anything we missed, guys? Like, can you think of anything? >> Covered a lot. >> Yeah, most of my research is done. But >> if you were talking, if you were a college teacher and you were teaching a class and you covered all that we covered today, what do you think we missed? >> Uh, I'm going to skip this. >> Sugar, >> no, it's protein, creatine, >> and sugar. protein powder va >> I'm diabetic so I'm wondering >> uh just ask pragati no uh Sam >> just ask pragati if there's sugar in this but this protein powder with creatine and these nuts are really cool because eat a bit >> pean nuts >> it would be healthy one >> they're called butter pean nuts >> okay I'll try >> [music] [music] >> and the base is tofu.
155:05 >> Yeah. So what did we miss as the question >> in in every part of our business there are startups there have been startups >> like somebody who starting at the age of 25 >> startup and u some some kind of a belief system in next 5 years time we'll make a mark >> these are time taking things lot of patience and once you basically talk about R&D you talk about patience >> the first thing is that mhm M >> mankind is a good example of success.
155:40 >> Yeah. >> They took the traditional business model and disrupted it. >> They were seen as a disruptor. But then we were always telling our sales reps see how much mankind guy is doing. How how come we are not growing at that pace? Oh, they said what they do we can't do. I said why not? Because they're this they're that this compensation systems are different. all kinds of excuses but you came and turned it around so there is something there to disrupt in all of our businesses >> is there patient feedback company somebody can start say for example I'm taking your man force whatever product or um your GLP1 what if somebody comes in and builds a company where there's an application where the patient every day reports back on video to an AI how he's feeling and I can sell the data back to you.
156:37 >> Never heard about this. >> Uh worth thinking but uh why a patient will give a feedback? >> My question is that what is attraction to him? What would you pay to him? >> Maybe like I don't know 50 rupees a day. >> So question is question is that I mean will it be very expensive or not? And how will you monetize? M >> so point is when uh somebody's taking a medicine >> the effect comes out a few days >> it takes time >> fair I would say there's still opportunity here right I think we have we haven't figured out because we have our lens of large company large size >> revenue streams you talked a lot about AI everywhere >> I tell you honestly one one thing which always haunts Let me finish the AI part.
157:33 So the the AI part >> is a big deal for us >> and we are not equipped to do it. >> Whether it's in our salesforce management, targeting doctors, all of that can be driven much more efficiently through agents and things like that. >> Our processes, R&D processes can improve. >> Now we are able to do >> uh insilic experiments, >> incilico organoids. These are all areas where there can be services to pharma which we don't have the caps to do >> and we can't attract the talent >> because a smart AI guy doesn't want to work for a you know pharmaceutical company.
158:12 >> So you would be willing to outsource that. >> It's actually a more than outsource. It's really a core process for us if >> we can do that. >> My idea is very simple. I mean approximately 1.5 to 2% of medicines get expired >> where these expiry expired medicines go >> in some place to be properly burned >> destroyed >> destroyed >> right >> and this is totally unorganized >> and there I mean there lies a scope >> so you'll pay money for somebody to take it from you and destroy it >> making that it does not come back in the market.
158:55 >> That's a big problem, right? Counter coming back. >> Yeah. It see Example every company is uh >> basically has a pledge to take the expiry back and give the price the money back to the consumer. >> But what I take the expiry, I burn it, I give to some some agency, it does not burn, it sells in the market, it again comes back. M >> can some company give this kind of a guarantee properly I mean using technology video AI whatever that I am burning it >> I give you guarantee I give you a certificate all these things are there because apart from this government agencies are involved because when you burn some chemical >> you pollute the area >> so in a very remote place it's certain red zones you can open that I tell you honestly this good one right >> I mean see people always look at a glamorous side why don't you look at some basic unglamorous thing which is basically need of the are sometimes you find that unglamorous things are more profitable >> glamorous [clears throat] the I mean looking at your idea about expiry medicines in the US I saw an NGO which does If the shelf life is less than some months, they take your medicines free of cost and distribute to patients who need them. I mean, it's not a business, but it's philanthropy.
160:31 >> We need to have controls. But in US this is >> what controls? I'm giving it to NG. NG is selling back getting the money and then using the money somewhere else. >> Yeah. But I'm just saying this happened. I'm telling you the the idea is not bad. The idea is very good. >> I mean 6 months before a product gets expired it goes out of circulation. >> What to do and again I mean for example let me talk about the expiry product >> very basic basic just a common sense >> at 100 mig when it reaches to 95 it is expired. M >> right. What if a poor patient takes 95 plus something a bit more >> efficacy is 95 >> who has no access to medicine?
161:24 >> It's a very wild thing. I'm ask saying >> you know this can go sideways if you don't >> I'm not saying >> can a product become poison? Yes, absolutely >> it can >> see a milligram can cure you that means a milligram can also hurt you that's not >> when when my my question is you can tell >> is important >> if for example shelf life of a drug is 2 years right example if I take something after 2 years and 2 months >> I wouldn't do that I'll tell you why I'll tell I'll give you my logic the shelf life was arrived at the rigorous statistical analysis of all the data that the drug is good only for this time. You don't want to violate that and then the whole thesis of how you do business goes off.
162:12 6 months before that expiry. >> That's what I'm saying. When there's short dating, people are giving donating the medicines. That is >> somebody guarantee that >> you can't test the drug to see if it's okay. >> Like a 2 and a half year old. >> See the government also needs some real rules to enforce, right? They have given you 2 years lifetime based on the data you submitted. >> You can always extend it if you produce more data, >> right?
162:39 >> And then say that you please extend it >> and then you can do it. But without doing that if you can't you can't do anything I think that's not a right thing to do. >> I talk from business point of view. We talk from science point of view. >> Not science. This is not science. This is rules. No. >> But it's nice. You both have a good contradiction going. >> I talk from the idiot point of view.
162:59 [laughter] >> Anything else that you can think of for somebody young to start or think about? You see I tell you honestly when when people start the business the problem is what they copy a set formula. >> Mhm. >> That this is the way these companies have become successful and that is totally wrong. >> Never ever follow a set formula. Example I [clears throat] gave you >> leave it here it's fine.
163:30 >> I'll leave it there. I'll keep >> the set formula was >> launch all India. M >> he said no only western >> UP >> proof of concept in western UP >> then expand slowly gradually so idea of following somebody's set formula is always wrong >> I say launch in a city >> very less >> that's a good lesson yeah very good for entrepreneurs see first of all you become I mean lo H that's a good strategy actually >> but I we believe always focused approach 100%.
164:12 >> Find a mini market succeed and then plan >> always and go in a market where nobody's going because there's always some place which is which can be competition free zone. I mean just look at this e-commerce when e-commerce came. So first it was Amazon and Flipkart everybody came flopped closed down. Then somebody said no no I'm only focusing narrowing down myself to cosmetics or clothing right or something else. Then somebody said no quick commerce.
164:51 Did they follow? They took the inspiration but for created a different path. So any any any time I mean looking what is visible should not be seen should not be followed ever that's that we always follow you know if I if I had a bunch of >> genius AI guys >> I would create a lab in my office for them and say this is the company this is my cost structure these are my cycle times >> these are my problems >> it's Not a farmer business but it's an AI business.
165:30 >> If you had to ask your kids to join your business or to build something similar would you? >> I would ask them to learn the business >> and the business is of a much larger size >> then they will be able to you know >> run until they're in the business for a decade and I don't think they have that kind of >> my one of my son is in diagnostic business. M >> the second has been put on the R&D side.
165:58 >> I know my priorities. If I say that next uh focus area of ours would be R&D. So I'm putting my bets over there >> and diagnostics because going forward I mean this is going to play a big role. >> Diagnostics, >> home diagnostics. >> I mean this we we sell Prager news. It's what it's a kit for just to check your pregnancy. >> How much we sell? >> Yeah. 300 cr rupees worth. >> I think the game changer will be when you can take blood on your own.
166:30 >> Yeah, >> somebody who is trying that. No, >> you you can still take a drug. >> People do it for measuring their blood sugar. >> Micrfluidics are coming in which can give a lot more data with just that one block >> like that. Therenos >> theranos was a fraud but that's the idea. >> Yeah, >> that's possible. It's possible >> like in one drop of blood I can find out my liver enzyme, my cholesterol, all of that.
166:55 >> People trying to do cancer with that one drop. Yeah. >> Some screening. >> I think that's it. We recorded for 4 and 1/2 hours. >> Wow. >> Which is a long time. [laughter] >> I'm not sure you got something your audience would be interested in. But >> no, no, it's interesting. See the thing is it's not even that >> here is the option you should go do it. >> It's also figuring out what can't be done.
167:23 >> Yeah. Yeah. >> It's useful. >> So if you don't think of it as a fast build business. >> Yeah. >> This is a great business to be in. >> Yeah. >> But you should have a decade to build it. >> Yeah. >> Yeah. >> A good example is Anthem 32,000 crores. >> Yeah. [laughter] >> Guy was an employee. Any last words? You guys want to say something to the audience? >> There's nothing shortcut. I mean, you have to be very very patient if you want to come in this line >> and the best way to start your business is first to take some experience >> in some area where you want to basically focus later on. It's always good I mean without risking your money, >> right?
168:05 >> You're getting the experience. So I I I'd say that uh the pharmaceutical business is great business for India. If you take out the IT sector, this is a business which is takes products to all over the world. >> Mhm. >> This sold as branded products in many parts of the world and I think huge impact. Uh so I very proud of what we have [snorts] done and I think there's more that we can do. um pharmacy of the world doesn't happen very fast if if you're called of course it's albeit generic pharmacy in the world but you know it's a good foundation to build on I think the next frontier is finding new drugs >> I feel I mean uh next 10 years would be very interesting >> extremely interesting for Indian pharma industry because once you know that um if you basically are cognizant to the future future challenge challenges, you take uh proactive actions.
169:08 >> Mhm. >> Super. Thank you so much for doing this. I [snorts] hope you didn't get too bored. >> No, thank you very much. Thank you. [music] >> Thanks all. >> Thank you very much. >> Middle of May. [laughter] >> Different kind of a dinner podcastike. Yeah. >> [music] >> When we were researching you, >> we learned that you like taking photographs of birds.
169:41 >> Yes, I do. >> We would have never expected it. What is the story? >> I, you know, it's from my childhood. I was always interested in nature. >> It's not photography is my interest. Nature is my interest. M >> so I one of my friends who lives down the road was a businessman and a very good ornithologist >> so introduced me to birds and that's how I started birding [music] then it became a passion and uh book I published some books and I also uh go on trips for birding >> what's your idea of a fun weekend Saturday Sunday what will you do >> I don't know it's what fun. But if I had an ideal weekend, I would go to the farm or something. Um, and the weather is not like this, but it's nice and I uh shoot some pictures. I visit my parents, my mother, but my father has passed away.
170:38 My mother spend some time with her and then maybe in the evening uh meet some friends. >> It's very interesting. >> And for you? For me the idea of uh fun >> fun weekend >> friends [music] drinking h in Delhi >> any >> [laughter]
Summary
- India is known as the "pharmacy of the world" by volume, but its revenue share is minimal compared to global standards.
- The pharmaceutical industry faces challenges, including safety incidents and operational difficulties, leading to personal struggles for leaders.
- Young entrepreneurs are encouraged to explore opportunities in the pharmaceutical sector, particularly in drug innovation and wellness products.
- The conversation highlights the importance of building a unique brand and understanding market dynamics rather than following established formulas.
- The rise of biologics and peptides presents new avenues for growth, with India needing to enhance its capabilities in these areas.
- The generics market is dominated by a few major players, with significant competition and a focus on affordability and accessibility.
- There is a growing interest in wellness and preventive health, particularly in the wake of the COVID-19 pandemic, creating opportunities for startups.
- Ethical marketing and patient education are emphasized as critical components of success in the pharmaceutical industry.